Process for preparing cyclo-glycyl-l-2-allylproline

A scalable and efficient process for producing cyclo-glycyl-L-2-allylproline using ammonia reagents in controlled organic solvent conditions addresses the inefficiencies of existing methods, achieving high yields and purity for clinical applications.

WO2026232200A1PCT designated stage Publication Date: 2026-11-12NEUREN PHARMACEUTICALS LIMITED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/AU2026/050461
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

The existing process for preparing cyclo-glycyl-L-2-allylproline (cG-2-AllylP) is inefficient and not scalable for clinical investigation and manufacture, with low yields and the use of reagents like TFA and Et3N leading to impurity formation and purification challenges.

Method used

A scalable process involving a cyclisation reaction using an ammonia reagent in the presence of specific organic solvents and controlled conditions to produce high-purity cyclo-glycyl-L-2-allylproline, avoiding impurities and enabling large-scale production.

Benefits of technology

The process achieves high yields and purity of cyclo-glycyl-L-2-allylproline, suitable for clinical development, by optimizing reaction conditions and solvent use to minimize impurities and facilitate scalable production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000001_0001
    Figure IMGF000001_0001
  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000003_0001
    Figure IMGF000003_0001
Patent Text Reader

Abstract

The present disclosure provides a process for the synthesis of a bicyclic glycine-proline compound, specifically cyclo-glycyl-L-2-allylproline (cG-2-AllylP). The present disclosure also relates to compounds prepared by the processes and the use of such compounds to prepare compositions and to treat disorders. In particular, there is also provided herein compositions comprising a bicyclic glycine-proline compound and, if present, defined impurities at minimal levels.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PROCESS FOR PREPARING CYCLO-GLYCYL-L-2-ALLYLPROLINE

[0002] Field

[0003] The present disclosure generally relates to a process for the synthesis of a bicyclic glycine-proline compound, and particularly cyclo-glycyl-L-2-allylproline (cG-2-AllylP). The present disclosure also relates to compounds prepared by the processes and the use of such compounds to prepare compositions and to treat disorders.

[0004] Background

[0005] Cyclo-glycyl-L-2-allylproline, also known as cyclic G-2-AllylP and cG-2-AllylP, is a synthetic analogue of the neurotrophic peptide, cyclic glycine proline (cGP). cGP occurs naturally in the brain and is believed to be associated with a series of neurophysiological effects, although its precise mechanism of action remains unknown.

[0006]

[0007] cG-2-AllylP

[0008] cG-2-AllylP has been investigated as the clinical candidate, NNZ-2591, and has demonstrated efficacy in pre-clinical models of Parkinson’s disease, stroke, traumatic brain injury, peripheral neuropathy, Fragile X Syndrome, memory impairment, multiple sclerosis, Phelan-McDermid Syndrome, Pitt Hopkins Syndrome, Angelman Syndrome and Prader-Willi Syndrome.

[0009] To date, the reported process for preparing cG-2-AllylP comes from the international PCT publication W02005 / 023815, and is shown in Scheme 1, below. According to the reported process, oxazolidinone 2 can be synthesised by reacting chloral with (S)-proline. This oxazolidinone 2 is then deprotonated using lithium diisopropylamide (LDA), followed by reaction with allyl bromide to produce allyl-oxazolidinone 3. Reaction of the allyl-oxazolidinone 3 with anhydrous hydrogen chloride (generated by reaction of acetyl chloride with methanol) forms the ring-opened monocyclic ester 4 as the hydrochloride salt, which is then reacted with N-boc-protected glycine 5 to form the dipeptide 6. An N-terminusdeprotection of dipeptide 6 is provided using an acid, followed by a cyclisation reaction using a weak base for elimination of the methoxy group of the methyl ester, to obtain the bicyclic glycine-proline compound 1, cG-2-AllylP.

[0010]

[0011] Scheme 1. Reagents, conditions, and yields: (i) LDA, THF, -78 °C, allyl bromide, -78 °C -30 °C, N2, 4 h (60%); (ii) acetyl chloride, CH3OH, reflux, N2, 24 h (63%); (iii) Et3N, BoPCl, CH2Cl2, RT, N2, 19.5 h (45%); (iv) TFA, CH2Cl2, 1 h, then Et3N, CH2C12, 23 h (37%).

[0012] A drawback to the reported process is the inability to efficiently scale this chemistry to the quantities that are required for clinical investigation and manufacture for clinical development.

[0013] This is highlighted in particular by the yields of each reaction step, which combine to provide a total yield over the four reaction steps of approximately 6%. This is, in part, due to purification being required at each step, typically in the form of flash chromatography. Such flash chromatography is not viable in the purification of large-scale quantities. It was also found that the use of TFA (trifluoroacetic acid) and Et3N (triethylamine) for the cyclisation step can result in a mixture of salts being formed from which it is difficult to isolate NNZ-2591 as a free compound.

[0014] Accordingly, there remains a need for an efficient and safe scalable process for preparing cG-2-AllylP and its analogues in good yields and high purity.Summary

[0015] The subject matter of the present disclosure is predicated in part on the development of an efficient and safe scalable process for preparing bicyclic glycine-proline compounds, including cG-2-AllylP.

[0016] It will be appreciated that other aspects, embodiments, and examples of the compounds, pharmaceutical compositions, methods, or uses, are further described herein.

[0017] In one aspect, there is provided a process for preparing a bicyclic glycine-proline compound of Formula 1 comprising a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1:

[0018]

[0019] Formula 2 Formula 1;

[0020] wherein R1is a terminal group; and X1is a halogen.

[0021] In some embodiments, the cyclisation reaction is performed in the presence of an ammonia reagent.

[0022] In some embodiments, the process further comprises preparing a compound of Formula 2 via an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0023]

[0024] Formula 3 Formula 4 Formula 2;

[0025] wherein R1is a terminal group; X1is a halogen; and X2is a halogen.

[0026] In a further aspect, there is provided a process for preparing a compound of Formula 2 comprising an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0027]

[0028] Formula 3 Formula 4 Formula 2;

[0029] wherein R1is a terminal group; X1is a halogen; and X2is a halogen.

[0030] In some embodiments, the process further comprises reacting a compound of Formula 2 to form the compound of Formula 1:

[0031]

[0032] Formula 2 Formula 1;

[0033] wherein R1is a terminal group; and X1is a halogen.

[0034] In some embodiments, the bicyclic glycine-proline compound of Formula 1 is a bicyclic glycine-proline compound of Formula 1(R):

[0035]

[0036] In a further aspect, there is provided a bicyclic glycine-proline compound of Formula1:

[0037]

[0038] Formula 1;

[0039] prepared by the process as described herein.

[0040] In other aspects or embodiments, there is provided a compound of Formula 2, Formula 3, Formula 5, Formula 5a, or Formula 6, prepared from any one or more processes as described by the above aspects, or any embodiments or examples thereof as described herein.

[0041] In other aspects or embodiments, there is provided a composition comprising a compound of any one of Formula 1, Formula 2, Formula 3, Formula 5, Formula 5a, or Formula 6, or any embodiments or examples thereof as described herein. The compounds in the compositions can be provided in high purity and / or with low amounts of one or more impurities (e.g. by-product and / or reagent) according to any embodiments or examples thereof as described herein. In other aspects there may be pharmaceutical compositions comprising the compounds or compositions thereof and one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0042] In some embodiments, there is provided a composition comprising a compound of Formula 1:

[0043]

[0044] Formula 1;

[0045] wherein Impurity b:

[0046]

[0047] Impurity b;if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0048] In some embodiments, there is provided a composition comprising a compound of Formula 1:

[0049]

[0050] Formula 1;

[0051] wherein Impurity g:

[0052]

[0053] Impurity g;

[0054] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0055] In some embodiments, there is provided a composition comprising a compound of Formula 1:

[0056]

[0057] Formula 1;

[0058] wherein Impurity h:

[0059]

[0060] Impurity h;if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0061] In some embodiments, there is provided a composition comprising a compound of Formula 1:

[0062]

[0063] Formula 1;

[0064] wherein a compound of Formula 2:

[0065]

[0066] Formula 2;

[0067] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001, wherein R1is a terminal group; and X1is a halogen. In some embodiments, X1is selected from the group consisting of chlorine and bromine.

[0068] In some embodiments, there is provided a composition comprising a compound of Formula 1:

[0069]

[0070] Formula 1;

[0071] wherein Impurity 2a:

[0072]

[0073] Impurity 2a;

[0074] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001.

[0075] In some embodiments, there is provided a composition comprising a compound of Formula 1:

[0076]

[0077] Formula 1;

[0078] wherein Impurity 1:

[0079]

[0080] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0081] In some embodiments, there is provided a composition comprising a compound of Formula 1:

[0082]

[0083] Formula 1;

[0084] wherein Impurity j:

[0085]

[0086] Impurity j;

[0087] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0088] In some embodiments, there is provided a composition comprising a compound of Formula 1:

[0089]

[0090] Formula 1;

[0091] wherein Impurity k:

[0092]

[0093] Impurity k;

[0094] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0095] In some embodiments, there is provided a composition comprising a compound of Formula 1(R):

[0096]

[0097] Formula 1(R);

[0098] wherein Impurity 1(S):

[0099]

[0100] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0101] In some embodiments, there is provided a composition comprising a compound of Formula 1:

[0102]

[0103] Formula 1;

[0104] wherein Impurity c:

[0105]

[0106] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0107] The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally-equivalent products, compositions and methods are clearly within the scope of the invention as described herein.

[0108] Throughout this specification, unless specifically stated otherwise or the context requires otherwise, reference to a single step, composition of matter, group of steps or group ofcompositions of matter shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of matter, groups of steps or group of compositions of matter.

[0109] Detailed Description

[0110] General Definitions

[0111] Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., chemistry, biochemistry, medicinal chemistry, microbiology and the like).

[0112] As used herein, the term “and / or”, e.g., “X and / or Y”, shall be understood to mean either " X and Y" or " X or Y" and shall be taken to provide explicit support for both meanings or for either meaning, e.g., A and / or B includes the options i) A, ii) B, or iii) A and B.

[0113] As used herein, the term “about”, unless stated to the contrary, refers to + / - 20%, typically + / - 10%, typically + / - 5%, of the designated value.

[0114] As used herein, the terms “a”, “an”, and “the” include both singular and plural aspects, unless the context clearly indicates otherwise.

[0115] It is to be appreciated that certain features that are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any sub-combination.

[0116] Throughout the present specification, various aspects and components of the invention can be presented in a range format. The range format is included for convenience and should not be interpreted as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range, unless specifically indicated. For example, description of a range such as from 1 to 5 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 5, from 3 to 5 etc., as well as individual and partial numbers within the recited range, for example, 1, 2, 3, 4, 5, 5.5 and 6, unless where integers are required or implicit from context. This applies regardless of the breadth of the disclosed range. Where specific values are required, these will be indicated in the specification.Throughout this specification the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

[0117] It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents form part of the common general knowledge in the art in the United States, Australia, or in any other country.

[0118] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the present specification, including definitions, will prevail. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

[0119] Salts may be formed in the case of embodiments of the compounds of Formulae 1 to 7, which contain a suitable acidic or basic group. Suitable salts of the compounds of Formulae 1 to 7 include those formed with organic or inorganic acids or bases. Accordingly, it will be appreciated, that in referring to a compound by its formula (i.e., Formula 1), reference is made to both the free-base / free-acid compound, and the corresponding salt thereof.

[0120] As used herein, the phrase “pharmaceutically acceptable salt” or a like term refers to pharmaceutically acceptable organic or inorganic salts. It will be appreciated that any reference to “salt” herein can include “pharmaceutically acceptable salts”. Exemplary acid addition salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, isonicotinate, lactate, salicylate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1 ' -methylene-bis-(2-hydroxy-3-naphthoate)) salts. Exemplary base addition salts include, but are not limited to, ammonium salts, alkali metal salts, for example those of potassium and sodium, alkaline earth metal salts, for example those of calcium and magnesium, and salts with organic bases, for example dicyclohexylamine, N-methyl-D-glucamine, morpholine, thiomorpholine, piperidine,pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl -propylamine, or a mono-, di- or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and / or one or more counterions. It will also be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the present disclosure since these may be useful as intermediates in the preparation of pharmaceutically acceptable salts or may be useful during storage or transport.

[0121] In the process described herein, any one or more of the reagents may be provided as the free acid / base, or otherwise in salt form. For example, a compound of Formula 5a may be reacted in step 3a as the free base, the hydrochloride salt, or as an otherwise suitable salt form.

[0122] Those skilled in the art of organic and / or medicinal chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as “solvates”. For example, a complex with water is known as a “hydrate”. As used herein, the phrase “pharmaceutically acceptable solvate” or “solvate” refer to an association of one or more solvent molecules and a compound of the present disclosure. Examples of solvents that form pharmaceutically acceptable solvates include, but are not limited to, water, isopropyl alcohol, ethanol, methanol, dimethylsulfoxide, ethyl acetate, isopropyl acetate, acetic acid, and ethanolamine. It will be understood that the present disclosure encompasses solvated forms, including hydrates, of the compounds of Formula 1 and salts thereof.

[0123] The compounds of the present disclosure may contain chiral (asymmetric) centers or the molecule as a whole may be chiral. The individual stereoisomers (enantiomers and diastereoisomers) and mixtures of these are within the scope of the present disclosure.

[0124] As used herein, the term “stereoisomer” refers to compounds having the same molecular formula and sequence of bonded atoms (i.e., atom connectivity), though differ in the three-dimensional orientations of their atoms in space. As used herein, the term “enantiomers” refersto two compounds that are stereoisomers in that they are non- superimposable mirror images of one another. Relevant stereocenters may be denoted with (R)- or (S)- configuration.

[0125] Those skilled in the art of organic and / or medicinal chemistry will appreciate that the compounds of Formula 1 and salts thereof may be present in an amorphous form or in a crystalline form. It will be understood that the present disclosure encompasses all forms and polymorphs of the compounds of Formula 1 and salts thereof.

[0126] Implicit hydrogen atoms (such as the hydrogen atoms present on the pyrrole ring, etc.) are omitted from the formulae for clarity, but would be understood by the skilled person to be present.

[0127] As used herein, the term “alkyl” encompasses both straight-chain (i.e., linear) and branched-chain hydrocarbon groups. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, i-butyl, sec-butyl, pentyl, and hexyl groups. In one example, the alkyl group is of one to eight carbon atoms (i.e. Ci-salkyl). In one example, the alkyl group is of one to six carbon atoms (i.e. Ci-6alkyl).

[0128] As used herein, the term “terminal group” refers to a chemical moiety, typically adjacent to a carbonyl moiety, that acts as a leaving group during a chemical reaction (e.g., the cyclisation reaction, as described herein). In one example, the terminal group is -OH. In one example, the terminal group is -OCi-6alkyl.

[0129] As used herein, the term “substantially free”, particularly when used in relation to a composition comprising, for example, a predominant compound (by weight) and an impurity, refers to that impurity being present in the composition in a trace amount, for example, less than about 0.5, less than about 0.1, less than about 0.01, or less than about 0.001 weight % of the amount of the predominant compound in the composition. In some embodiments, “substantially free” refers to a composition comprising an impurity in which the impurity is present in such a low amount that it is barely detectable in the composition. It will be appreciated that a composition that is “substantially free” of an impurity, in some embodiments, describes a composition in which the impurity does not affects the desired properties or activity of the predominant compound in that composition. In one example, “substantially free” of an impurity means the impurity is present in an amount of less than about 0.01 weight % of the amount of the predominant compound in the composition. In one example, “substantially free” of an impurity means the impurity is present in an amount of less than about 0.001 weight % of the amount of the predominant compound in the composition.All documents cited or referenced herein, and all documents cited or referenced in herein cited documents, together with any manufacturer’s instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference in their entirety.

[0130] Process for Preparing a Compound of Formula 1

[0131] The subject matter of the present disclosure is predicated in part on the discovery of an efficient, safe, and scalable process for preparing a bicyclic glycine-proline compound of Formula 1(R) (cG-2-AllylP). Scheme 2, below, provides an example of an efficient, safe, and scalable process for preparing a bicyclic glycine-proline compound of Formula 1(R) (cG-2-AllylP).

[0132]

[0133] Formula 1(R) Formula 5a Formula 3(R) Formula 2(R) cG-2-AllylP

[0134] Scheme 2. Exemplary process for the preparation of a bicyclic glycine-proline compound of Formula 1(R) (cG-2-AllylP).

[0135] The above process is described further below in relation to each of the steps of the process. Each step may provide its own independent process aspect, embodiment, or example for preparing an intermediate or compound per se, or may provide a further embodiment or example to another process aspect or embodiment as described herein. Each intermediate or prepared compound of each step may also provide its own independent aspect, embodiment, or example, in relation to compounds, compositions, and / or processes thereof.

[0136] Synthesis of a Compound of Formula 1 - Cyclisation Reaction

[0137] The present disclosure provides a process for preparing a bicyclic glycine-proline compound of Formula 1:

[0138]

[0139] Formula 1.

[0140] In one example, the bicyclic glycine -proline compound of Formula 1 is the bicyclic glycine-proline compound of Formula 1(R):

[0141]

[0142] Formula!( / ?).

[0143] In some embodiments, the process for preparing a bicyclic -proline compound of Formula 1 comprises a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1:

[0144]

[0145] Formula 2 Formula 1;

[0146] wherein R1is a terminal group; and X1is a halogen. Herein, this process is referred to as the “cyclisation reaction”.

[0147] In some embodiments, the process for preparing a bicyclic -proline compound of Formula 1(R) comprises a cyclisation reaction of a compound of Formula 2(R) to form the compound of Formula 1(R):

[0148]

[0149] Formula 2(R) Formula 1(R);wherein R1is a terminal group; and X1is a halogen.

[0150] In some embodiments, R1is a terminal group. As used herein, the term “terminal group” refers to a group, or substituent, bonded directly to the -C(O)- of Formula 2, that acts as a leaving group during the cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1. In some embodiments, R1is a leaving group. In some embodiments, R1is selected from the group consisting of -OH and -OC1-6alkyl. In one example, R1is -OH. In some embodiments, R1is -OCi-6alkyl. In one example, R1is -OC1alkyl (i.e., -OCH3). In one example, R1is -OC2alkyl. In one example, R1is -OC3alkyl. In one example, R1is -OC4alkyl. In one example, R1is -OC5alkyl. In one example, R1is -OCealkyl.

[0151] In some embodiments, X1is a halogen. In some embodiments, X1is a halogen selected from the group consisting of fluorine, chlorine, bromine, and iodine. In some embodiments, X1is selected from the group consisting of chlorine and bromine. In one example, X1is chlorine. In one example, X1is bromine. In one example, X1is fluorine. In one example, X1is iodine.

[0152] In some embodiments, the compound of Formula 2 is selected from the group consisting of:

[0153]

[0154] In one example, the compound of Formula 2 is a compound of Formula 2a:

[0155]

[0156] Formula 2a.

[0157] In one example, the compound of Formula 2 is a compound of Formula 2a(R):

[0158]

[0159] Formula 2a( / ?).

[0160] In some embodiments, there is provided a process for preparing a bicyclic glycineproline compound of Formula 1 comprising a cyclisation reaction of a compound of Formula 2 in the presence of an ammonia reagent to form the compound of Formula 1:

[0161]

[0162] Formula 2 Formula 1;

[0163] wherein R1is a terminal group; and X1is a halogen.

[0164] As used herein, the term “ammonia reagent” refers to a reagent that provides a source of ammonia in situ during the cyclisation reaction. The ammonia reagent may be any ammonia reagent that provides a source of ammonia in situ during the cyclisation reaction. In some embodiments, the ammonia reagent is selected from the group consisting of ammonia and sodium amide. In some embodiments, the ammonia reagent is selected from the group consisting of ammonia in organic solvent, gaseous ammonia, liquid ammonia (e.g., anhydrous), and sodium amide. In one example, the ammonia reagent is gaseous ammonia. In one example, the ammonia reagent is liquid ammonia. In one example, the ammonia reagent is sodium amide.

[0165] When the ammonia reagent is ammonia in an organic solvent, it will be appreciated that the organic solvent may be any suitable organic solvent. Examples of organic solvents include, but are not limited to, tetrahydrofuran (THF) and dioxane. In one example, the organic solvent is tetrahydrofuran (THF), and the ammonia reagent is ammonia in tetrahydrofuran (THF). In other embodiments, the organic solvent is an alcoholic solvent. When the ammonia reagent is ammonia in alcoholic solvent, it will be appreciated that the alcoholic solvent may be any suitable alcoholic solvent. In some embodiments, the ammonia reagent is ammonia in an alcoholic solvent selected from the group consisting of ammonia in methanol solvent, ammonia in ethanol solvent, ammonia in isopropanol solvent, and combinations thereof. In someembodiments, the ammonia reagent is ammonia in an alcoholic solvent selected from the group consisting of ammonia in methanol solvent, ammonia in isopropanol solvent, and combinations thereof. In one example, the ammonia reagent is ammonia in methanol solvent. In one example, the ammonia reagent is ammonia in ethanol solvent. In one example, the ammonia reagent is ammonia in isopropanol solvent.

[0166] The ammonia reagent may be provided in the cyclisation reaction at a particular concentration, defined by molality (N, total moles of a solute per kilogram of solvent, or solute concentration in a mass of solution). In some embodiments, the ammonia reagent is provided in a concentration of at least about 0.5 N, 1.0 N, 2.0 N, 3.0 N, 4.0 N, 5.0 N, 6.0 N, 7.0 N, 8.0 N, 9.0 N, or 10 N. In one example, the ammonia reagent is provided in a concentration of greater than about 1.0 N. In one example, the ammonia reagent is provided in a concentration of greater than about 2.0 N. In one example, the ammonia reagent is provided in a concentration of greater than about 4.0 N. In some embodiments, the ammonia reagent is provided in a concentration of less than about 20 N, 10 N, 9.0 N, 8.0 N, or 7.0 N. In some embodiments, the ammonia reagent is provided in a concentration of between about 1.0 N and 10 N, between about 4.0 N and 9.0 N, or between about 6.0 N and 8.0 N. In one example, the ammonia reagent is provided in a concentration of about 7.0 N.

[0167] The ammonia reagent may be provided in the cyclisation reaction at a particular stoichiometric amount. This “stoichiometric amount”, which may also be referred to as a “stoichiometric ratio”, defines the number of moles of the reagent relative to another reagent. The term “molar equivalent” specifically refers to the ratio of moles of one reagent to the moles of another reagent. The ammonia reagent may be provided in the cyclisation reaction in any molar equivalent amount suitable so as to effect the cyclisation reaction. In some embodiments, the ammonia reagent is provided in a molar equivalent amount of ammonia of at least about 2, 5, 6, 7, 8, 9, or 10, relative to the molar amount of the compound of Formula 2. In some embodiments, the ammonia reagent is provided in a molar equivalent amount of ammonia of less than about 40, 30, 20, 15, or 10, relative to the molar amount of the compound of Formula 2. In some embodiments, the ammonia reagent is provided in a molar equivalent amount of ammonia of between about 0.1 and 40, between about 1.0 and 30, between about 5.0 and 25, or between about 5.0 to 20, relative to the molar amount of the compound of Formula 2. In one example, the ammonia reagent is provided in a molar equivalent amount of ammonia of about 10, relative to the molar amount of the compound of Formula 2.As will be appreciated by the person skilled in the art, the cyclisation reaction will be performed in a suitable solvent. In one example, the cyclisation reaction is performed in the presence of an organic solvent. In some embodiments, the cyclisation reaction is performed in the presence of an organic solvent selected from the group consisting of a chlorinated hydrocarbon solvent, an ether solvent, an organic nitrile solvent, and combinations thereof. In one example, the organic solvent is an organic nitrile solvent. In one example, the organic solvent is a chlorinated hydrocarbon solvent. In one example, the organic solvent is an ether solvent. In one example, the organic solvent is a combination of a chlorinated hydrocarbon solvent and an ether solvent.

[0168] Examples of organic nitrile solvents include, but are not limited to, acetonitrile. Accordingly, in one example, the organic solvent is acetonitrile.

[0169] Examples of chlorinated hydrocarbon solvents include, but are not limited to, dichloromethane, chloroform, carbon tetrachloride, trichloroethylene, and tetrachloroethylene. Accordingly, in one example, the organic solvent is dichloromethane. In one example, the organic solvent is chloroform.

[0170] Examples of ether solvents include, but are not limited to, diethyl ether, tetrahydrofuran, tetrahydropyran, 1,2-dimethoxyethane, methyl tert-butyl ether, 2-methyltetrahydrofuran, and 1,4-dioxane. Accordingly, in one example, the organic solvent is methyl tert-butyl ether. In one example, the organic solvent is tetrahydrofuran. In one example, the organic solvent is 2-methyltetrahydrofuran. In some embodiments, the organic solvent is selected from the group consisting of dichloromethane, methyl tert-butyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, and combinations thereof.

[0171] The person skilled in the art will appreciate that it may be necessary to apply heat to facilitate the cyclisation reaction. The amount of heat required may depend upon the solvent in which the reaction is performed in, as discussed above. In some embodiments, the cyclisation reaction is performed at least at about 10 °C, about 20 °C, about 30 °C, or about 40 °C. In some embodiments, the cyclisation reaction is performed at less than at about 50 °C, 45 °C, 40 °C, 35 °C, or 30 °C. In some embodiments, the cyclisation reaction is performed at between about 10 °C and 50 °C, between about 20 °C and 40 °C, or between about 25 °C and 35 °C. In one example, the cyclisation reaction is performed at about 30 °C.

[0172] As would be appreciated by the person skilled in the art, it is possible to monitor the progress of a reaction by measuring the conversion of the one or more reagents to the desiredproduct. This monitoring may occur through any suitable means as would be known to the person skilled in the art, including, for example, TLC (thin layer chromatography) and HPLC (high-performance liquid chromatography). With HPLC, for example, it is necessary to know the retention times of the reagents and products, and from here, the area under each peak can be analysed to calculate the relative amounts of reagents and product, and therefore the percentage conversion of reagents to the desired product. An aliquot of the reaction mixture may be taken at any time point during the reaction and analysed by HPLC. In some embodiments, the cyclisation reaction is monitored by HPLC. In some embodiments, an aliquot of the reaction mixture is taken at about one hour, five hours, 20 hours, and / or four days following commencement of the cyclisation reaction, and analysed by HPLC. In one example, an aliquot of the reaction mixture is taken at about 20 hours following commencement of the cyclisation reaction.

[0173] Accordingly, in some embodiments, the cyclisation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2 to the compound of Formula 1. In some embodiments, the cyclisation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 2 to the compound of Formula 1, when measured at about 20 hours following commencement of the reaction. In some embodiments, the cyclisation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2 to the compound of Formula 1 and when analysed by HPLC. In some embodiments, the cyclisation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 2 to the compound of Formula 1, when measured at about 20 hours following commencement of the reaction and when analysed by HPLC.

[0174] Similarly, as would also be appreciated by the person skilled in the art, it is possible to measure the yield of the reaction. As used herein, the term “yield” will be taken to mean the amount of either crude or purified compound obtained from a reaction, measured as a percentage of theoretical yield of the compound in that reaction, as would be understood by the person skilled in the art. In some embodiments, the cyclisation reaction provides a yield of a compound of Formula 1 of at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99%, as determined from a compound of Formula 2 starting reagent. In some embodiments, the cyclisation reaction provides a yield of a compound of Formula 1 of between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% as determined from a compound of Formula 2 starting reagent.In some embodiments, the cyclisation reaction provides a compound of Formula 1 in high purity. As would be understood by a skilled person, purity is a measure independent of yield. That is, a compound may have a high purity, albeit a low yield. As used herein, the term “high purity” refers to at least 80% of the ultimately obtained material being the desired compound (e.g., a compound of Formula 1), which may be measured, for example, by HPLC. The purity of a compound may be measured based on the crude reaction mixture, the product isolated from the reaction mixture (i.e., following the reaction work-up), or the purified product (i.e., following chromatography, recrystallization, etc.).

[0175] In some embodiments, the cyclisation reaction provides a compound of Formula 1 in at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity. Crystallisation can provide a purity of about 100%. In some embodiments, the cyclisation reaction provides a compound of Formula 1 in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 1 in the crude reaction mixture. In some embodiments, the cyclisation reaction provides a compound of Formula 1 in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 1 isolated from the reaction mixture (i.e., following the reaction work-up). In some embodiments, the cyclisation reaction provides a compound of Formula 1 following purification in at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the cyclisation reaction provides a compound of Formula 1 following recrystallization in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the cyclisation reaction provides a compound of Formula 1 following column chromatography in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity.

[0176] In some embodiments, the process for preparing a bicyclic glycine -proline compound of Formula 1 comprising a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1 beneficially avoids the generation of any one or more unwanted byproducts, impurities, or residues selected from the group consisting of:

[0177]

[0178] Impurity a; Impurity b; Impurity c;

[0179]

[0180] Impurity m.

[0181] In one example, the ammonia reagent in the cyclisation reaction is ammonia in methanol solution, and the process for preparing a bicyclic glycine -proline compound of Formula 1 comprising a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1, results in the reduced generation of Impurity b:

[0182]

[0183] Impurity b.In some embodiments, the process for preparing a bicyclic glycine -proline compound of Formula 1(R) comprising a cyclisation reaction of a compound of Formula 2(R) to form the compound of Formula 1(R) beneficially avoids the generation of any one or more unwanted byproducts, impurities, or residues selected from the group consisting of:

[0184]

[0185] Impurity d( / ?): Impurity e( / ?): Impurity f(7?);

[0186]

[0187] Impurity m( / ?): and Formula 1(S).In some embodiments, the cyclisation reaction occurs with a starting material amount of a compound of Formula 2 of at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, 40 kg, 50 kg, 100 kg, 250 kg, 500 kg, 750 kg, or 1000 kg. That is, the cyclisation reaction occurs on at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, 40 kg, 50 kg, 100 kg, 250 kg, 500 kg, 750 kg, or 1000 kg scale.

[0188] In some embodiments, the cyclisation reaction further comprises preparing a compound of Formula 2 via an A- acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0189]

[0190] Formula 3 Formula 4 Formula 2;

[0191] wherein R1is a terminal group; X1is a halogen; and X2is a halogen, as defined herein. That is, in some embodiments, the cyclisation reaction further comprises the A-acylation reaction, as described herein, to form the compound of Formula 2.

[0192] Synthesis of a Compound of Formula 2 - A- Acylation Reaction

[0193] The present disclosure provides a process for preparing a compound of Formula 2:

[0194]

[0195] Formula 2.

[0196] In one example, the compound of Formula 2 is the compound of Formula 2(R):

[0197]

[0198] Formula 2(R).In some embodiments, the process for preparing a compound of Formula 2 comprises an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0199]

[0200] Formula 3 Formula 4 Formula 2;

[0201] wherein R1is a terminal group; X1is a halogen; and X2is a halogen. Herein, this process is referred to as the ‘W-acylation reaction”. In some embodiments, the N-acylation reaction occurs under Schotten-Baumann reaction conditions, or a variation thereof.

[0202] In some embodiments, the process for preparing a compound of Formula 2(R) comprises an N- acylation reaction of a compound of Formula 3(7 ) with a dihalide compound of Formula 4:

[0203] F

[0204]

[0205] wherein R1is a terminal group; X1is a halogen; and X2is a halogen.

[0206] In some embodiments, R1is a terminal group. In some embodiments, R1is a leaving group. In some embodiments, R1is selected from the group consisting of -OH and -OCi-6alkyl. In one example, R1is -OH. In some embodiments, R1is -OCi-6alkyl. In one example, R1is -OC1alkyl (i.e., -OCH3). In one example, R1is -OC2alkyl. In one example, R1is -OC3alkyl. In one example, R1is -OC4alkyl. In one example, R1is -OC5alkyl. In one example, R1is -OC6alkyl.

[0207] In some embodiments, X1is a halogen. In some embodiments, X1is a halogen selected from the group consisting of fluorine, chlorine, bromine, and iodine. In some embodiments, X1is selected from the group consisting of chlorine and bromine. In one example, X1is chlorine. In one example, X1is bromine. In one example, X1is fluorine. In one example, X1is iodine.

[0208] In some embodiments, X2is a halogen. In some embodiments, X2is a halogen selectedfrom the group consisting of fluorine, chlorine, bromine, and iodine. In some embodiments, X2is selected from the group consisting of chlorine and bromine. In one example, X2is chlorine. In one example, X2is bromine. In one example, X2is fluorine. In one example, X2is iodine. It will be appreciated that X1and X2may each be the same halide, or may otherwise each be a different halide.

[0209] In some embodiments, the dihalide compound of Formula 4 is selected from the group consisting of:

[0210]

[0211] Formula 4a; Formula 4b; Formula 4c; and Formula 4d.

[0212] In one example, the compound of Formula 4 is a compound of Formula 4a:

[0213]

[0214] Formula 4a.

[0215] The dihalide compound of Formula 4 may be provided in the N-acylation reaction in any molar equivalent amount suitable so as to effect the N-acylation reaction. In some embodiments, the dihalide compound of Formula 4 is provided in a molar equivalent amount of at least about 0.5, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5 or 2.0, relative to the molar amount of the compound of Formula 3. In some embodiments, the dihalide compound of Formula 4 is provided in a molar equivalent amount of less than about 10, 5, 3, 2, 1.5, 1.4, or 1.3, relative to the molar amount of the compound of Formula 3. In some embodiments, the dihalide compound of Formula 4 is provided in a molar equivalent amount of between about 0.1 and 20, between about 1.0 and 10, between about 1.1 and 5, or between about 1.2 and 1.7, relative to the molar amount of the compound of Formula 3. In one example, the dihalide compound of Formula 4 is provided in a molar equivalent amount of about 1.5, relative to the molar amount of the compound of Formula 3.

[0216] In one example, the compound of Formula 3 is a compound of Formula 3a:

[0217]

[0218] Formula 3a.In one example, the compound of Formula 3 a is a compound of Formula 3a(A):

[0219]

[0220] Formula 3a( / ?).

[0221] In some embodiments, the N-acylation reaction is performed in the absence of a base reagent. In some embodiments, the N-acylation reaction is performed in the presence of a base reagent.

[0222] In some embodiments, the base reagent is an anionic base. In some embodiments, the base reagent is provided by a metal salt comprising a metal cation and counter anion selected from a bicarbonate, carbonate, hydroxide, oxide, or phosphate. In some embodiments, the base reagent is a metal salt comprising a Group 1 metal cation and counter anion selected from a bicarbonate, carbonate, hydroxide, oxide, or phosphate. In one example, the Group 1 metal is lithium, sodium, or potassium. In one example, the Group 1 metal is sodium. In one example, the Group 1 metal is potassium. In some embodiments, the base reagent is a metal carbonate. The metal carbonate may for example be selected from potassium carbonate (K2CO3), and sodium carbonate (NaiCOs). In some embodiments, the base reagent is a phosphate. The metal phosphate may be selected from tripotassium phosphate (K3PO4), dipotassium hydrogen phosphate (K2HPO4), sodium phosphate (Na3PO4), and disodium hydrogen phosphate (Na2HPO4). In some embodiments, the base reagent is selected from the group consisting of sodium hydroxide (NaOH), potassium hydroxide (KOH), potassium carbonate (K2CO3), potassium bicarbonate (KHCO3), sodium carbonate (Na2CO3), sodium bicarbonate (NaHCOs), tripotassium phosphate (K3PO4), dipotassium hydrogen phosphate (K2HPO4), sodium phosphate (Na3PO4), disodium hydrogen phosphate (Na2HPO4), and combinations thereof. In one example, the base reagent is potassium carbonate (K2CO3). It will be appreciated that the base reagent may be provided as an aqueous solution. Accordingly, in one example, the base reagent is potassium carbonate (K2CO3), and the potassium carbonate (K2CO3) is provided as an aqueous solution.

[0223] In some embodiments, the base reagent is an organic base. As will be appreciated by the person skilled in the art, an organic base is an organic compound that acts as a base. Organic bases are typically proton acceptors. Examples of organic bases include, but are not limited to, nitrogen-containing organic compounds. In one example, the organic base is an alkylamine.Examples of alkylamines include, but are not limited to, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, and diisopropylethylamine (DIPEA). In one example, the base reagent is triethylamine. In one example, the base reagent is diisopropylethylamine (DIPEA). In one example, the organic base is an aniline. Examples of anilines include, but are not limited to, aniline, 4-methoxyaniline, A, A-dimethylaniline, 3-nitroaniline, and 4-trifluoromethylaniline. In one example, the base reagent is a pyridine derivative. Examples of pyridine derivatives include, but are not limited to, pyridine and pyrrolidine. In one example, the base reagent is an imidazole derivative. Examples of imidazole derivatives include, but are not limited to, imidazole and benzimidazole. In one example, the base reagent is quinoline. In one example, the base reagent is morpholine. In one example, the base reagent is piperidine. In one example the base is an amidine derivative. Examples of amidine derivates include, but are not limited to, diazabicycloundecene (DBU). In one example, the base reagent is diazabicycloundecene (DBU).

[0224] The base reagent is provided in the N-acylation reaction at a particular concentration, defined by molarity (M, total moles of a solute per litre of solution, or solute concentration in a volume of solution). In some embodiments, the base reagent is provided in a concentration of at least about 0.5 M, 1.0 M, 1.5 M, 2.0 M, or 5.0 M. In some embodiments, the base reagent is provided in a concentration of less than about 20 M, 10 M, 5.0 M, 4.0 M, 3.0 M, or 2.0 M. In some embodiments, the base reagent is provided in a concentration of between about 0.5 M and 10 M, between about 1.0 M and 5.0 M, or between about 1.5 M and 2.5 M. In one example, the base reagent is provided in a concentration of about 2.0 M.

[0225] In some embodiments, the base reagent is potassium carbonate (K2CO3), and is provided in a concentration of at least about 0.5 M, 1.0 M, 1.5 M, 2.0 M, or 5.0 M. In some embodiments, the base reagent is potassium carbonate (K2CO3), and is provided in a concentration of less than about 20 M, 10 M, 5.0 M, 4.0 M, 3.0 M, or 2.0 M. In some embodiments, the base reagent is potassium carbonate (K2CO3), and is provided in a concentration of between about 0.5 M and 10 M, between about 1.0 M and 5.0 M, or between about 1.5 M and 2.5 M. In one example, the base reagent is potassium carbonate (K2CO3), and is provided in a concentration of about 2.0 M.

[0226] The base reagent is provided in the N-acylation reaction at a particular stoichiometric amount. The base reagent may be provided in the N-acylation reaction in any molar equivalent amount suitable so as to effect the N-acylation reaction. In some embodiments, the base reagent is provided in a molar equivalent amount of at least about 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0,4.5, or 5.0, relative to the molar amount of the compound of Formula 3. In some embodiments, the base reagent is provided in a molar equivalent amount of less than about 10, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.5, 3.0, 2.5, or 2.0, relative to the molar amount of the compound of Formula 3. In some embodiments, the base reagent is provided in a molar equivalent amount of between about 0.5 and 5.0, between about 0.75 and 4.0, or between about 1.0 and 4.0, relative to the molar amount of the compound of Formula 3.

[0227] In some embodiments, the base reagent is potassium carbonate (K2CO3), and the potassium carbonate (K2CO3) may be provided in the N-acylation reaction in any molar equivalent amount suitable so as to effect the N-acylation reaction. In some embodiments, the base reagent is potassium carbonate (K2CO3), and is provided in a molar equivalent amount of at least about 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0, relative to the molar amount of the compound of Formula 3. In some embodiments, the base reagent is potassium carbonate (K2CO3), and is provided in a molar equivalent amount of less than about 10, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.5, 3.0, 2.5, or 2.0, relative to the molar amount of the compound of Formula 3. In some embodiments, the base reagent is potassium carbonate (K2CO3), and is provided in a molar equivalent amount of between about 0.5 and 5.0, between about 0.75 and 4.0, or between about 1.0 and 3.0, relative to the molar amount of the compound of Formula 3. In one example, the base reagent is potassium carbonate (K2CO3), and is provided in a molar equivalent amount of about 1.8, relative to the molar amount of the compound of Formula 3. In one example, the base reagent is potassium carbonate (K2CO3), and is provided in a molar equivalent amount of about 3.4, relative to the molar amount of the compound of Formula 3.

[0228] As will be appreciated by the person skilled in the art, the N-acylation reaction will be performed in a suitable solvent. In one example, the N-acylation reaction is performed in the presence of an organic solvent. In some embodiments, the N-acylation reaction is performed in the presence of an organic solvent selected from the group consisting of a chlorinated hydrocarbon solvent, an ether solvent, and combinations thereof. In one example, the organic solvent is a chlorinated hydrocarbon solvent. In one example, the organic solvent is an ether solvent. In one example, the organic solvent is a combination of a chlorinated hydrocarbon solvent and an ether solvent.

[0229] Examples of chlorinated hydrocarbon solvents include, but are not limited to, dichloromethane, chloroform, carbon tetrachloride, trichloroethylene, and tetrachloroethylene. Accordingly, in one example, the organic solvent is dichloromethane. In one example, the organic solvent is chloroform.Examples of ether solvents include, but are not limited to, diethyl ether, tetrahydrofuran, tetrahydropyran, 1,2-dimethoxyethane, methyl tert-butyl ether, 2-methyltetrahydrofuran, and 1,4-dioxane. Accordingly, in one example, the organic solvent is methyl tert-butyl ether. In one example, the organic solvent is tetrahydrofuran. In one example, the organic solvent is 2-methyltetrahydrofuran. In some embodiments, the organic solvent is selected from the group consisting of dichloromethane, methyl tert-butyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, and combinations thereof.

[0230] It may be preferable to initially cool the reaction mixture comprising the compound of Formula 3 prior to addition of the dihalide compound of Formula 4. In some embodiments, a reaction mixture comprising a compound of Formula 3 is initially cooled to between about -30 °C to 10 °C, between about -20 °C to 10 °C, or between about -10 °C to 10 °C, immediately prior to the reaction with a dihalide compound of Formula 4. In one example, a reaction mixture comprising a compound of Formula 3 is initially cooled to between about -10 °C to 10 °C immediately prior to the reaction with a dihalide compound of Formula 4.

[0231] Once the dihalide compound of Formula 4 has been added to the reaction mixture, it may be preferable to warm the reaction mixture. This temperature may be maintained until completion of the A-acylation reaction. In some embodiments, a reaction mixture comprising a compound of Formula 3 and a dihalide compound of Formula 4 is allowed to warm to between about 10 °C and 50 °C, between about 15 °C and 40 °C, between about 15 °C and 30 °C, or between about 15 °C and 25 °C, where the temperature is maintained until completion of the reaction. Completion of the reaction may be monitored by HPLC, as discussed herein. In some embodiments, the temperature of the reaction mixture is maintained for a reaction time (hours) of between about 1 and 12, between about 2 and 6, or between about 3 and 4.

[0232] In some embodiments, the A-acylation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2. In some embodiments, the A-acy lation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 3 to the compound of Formula 2, when measured at about 18 hours following commencement of the reaction. In some embodiments, the A-acylation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2 and when analysed by HPLC. In some embodiments, the A-acylation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversionof the compound of Formula 3 to the compound of Formula 2, when measured at about 18 hours following commencement of the reaction and when analysed by HPLC.

[0233] In some embodiments, the iV-acylation reaction provides a yield of a compound of Formula 2 of at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99%, as determined from a compound of Formula 3 starting reagent. In some embodiments, the A / - acylation reaction provides a yield of a compound of Formula 2 of between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% as determined from a compound of Formula 3 starting reagent.

[0234] In some embodiments, the iV-acylation reaction provides a compound of Formula 2 in at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity. Crystallisation can provide a purity of about 100%. In some embodiments, the AZ-acylation reaction provides a compound of Formula 2 in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 2 in the crude reaction mixture. In some embodiments, the iV-acylation reaction provides a compound of Formula 2 in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 2 isolated from the reaction mixture (i.e., following the reaction work-up). In some embodiments, the N-acylation reaction provides a compound of Formula 2 following purification in at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the iV-acylation reaction provides a compound of Formula 2 following recrystallization in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the N- acylation reaction provides a compound of Formula 2 following column chromatography in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity.

[0235] In some embodiments, the iV-acylation reaction beneficially avoids the generation of unwanted by-products, impurities, or residues. In some embodiments, preparing a compound of Formula 2 via an N- acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4 results in reduced generation of any one or more unwanted by-products, impurities, or residues selected from the group consisting of:

[0236]

[0237] Impurity n; Impurity o; and Impurity p;

[0238] wherein R1, X1, and X2are as described herein.

[0239] In some embodiments, preparing a compound of Formula 2a via an A / - acylation reaction of a compound of Formula 3a with a dihalide compound of Formula 4a results in reduced generation of any one or more unwanted by-products, impurities, or residues selected from the group consisting of:

[0240]

[0241] Impurity na; Impurity oa; and

[0242]

[0243] In some embodiments, preparing a compound of Formula 2a(R) via an iV-acylation reaction of a compound of Formula 3a(R) with a dihalide compound of Formula 4a results in reduced generation of any one or more unwanted by-products, impurities, or residues selected from the group consisting of:

[0244]

[0245] Impurity na( / ?); Impurity oa( / ?); and Impurity pa( / ?).In some embodiments, the iV-acylation reaction occurs with a starting material amount of a compound of Formula 2 of at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, 40 kg, 50 kg, 100 kg, 250 kg, 500 kg, 750 kg, or 1000 kg. That is, the A-acylation reaction occurs on at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, 40 kg scale, 50 kg, 100 kg, 250 kg, 500 kg, 750 kg, or 1000 kg.

[0246] In some embodiments, the A-acylation reaction further comprises reaction of a compound of Formula 2 to form the compound of Formula 1:

[0247]

[0248] Formula 2 Formula 1;

[0249] wherein R1is a terminal group; and X1is a halogen, as defined herein.

[0250] In some embodiments, the iV-acylation reaction further comprises reaction of a compound of Formula 2 in the presence of an ammonia reagent to form the compound of Formula 1:

[0251]

[0252] Formula 2 Formula 1;

[0253] wherein R1is a terminal group; and X1is a halogen, as defined herein. That is, in some embodiments, the A-acylation reaction further comprises the cyclisation reaction, as described herein, to form the bicyclic glycine -proline compound of Formula 1.

[0254] Overall Synthesis of a Bicyclic Glycine-Proline Compound of Formula 1

[0255] Provided herein is an example overall process for preparing a bicyclic glycine -proline compound of Formula 1(R) (cG-2-AllylP), as depicted in Scheme 3 below:

[0256]

[0257] Formula 1(R) Formula 5a Formula 3{R) Formula 2(R) cG-2-AllylP Scheme 3. Exemplary process for the preparation of a bicyclic glycine-proline compound of Formula 1(R) (cG-2-AllylP).

[0258] Accordingly, in some embodiments, the process for preparing a bicyclic -proline compound of Formula 1 comprises a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1:

[0259]

[0260] Formula 2 Formula 1;

[0261] wherein the process for preparing a compound of Formula 2 comprises an A-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0262]

[0263] Formula 3 Formula 4 Formula 2;

[0264] wherein R1is a terminal group; X1is a halogen; and X2is a halogen, as described herein.

[0265] In some embodiments, the process for preparing a bicyclic -proline compound of Formula 1 comprises a cyclisation reaction of a compound of Formula 2 in the presence of anammonia reagent to form the compound of Formula 1:

[0266]

[0267] Formula 2 Formula 1;

[0268] wherein the process for preparing a compound of Formula 2 comprises an AZ-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0269]

[0270] Formula 3 Formula 4 Formula 2;

[0271] wherein R1is a terminal group; X1is a halogen; and X2is a halogen, as described herein.

[0272] In some embodiments, the compound of Formula 2 may be isolated prior to the cyclisation reaction. In some examples, the compound of Formula 2 may be reacted in a subsequent reaction in situ or in crude form. In some examples, the compound of Formula 2 may be reacted without isolation and / or purification (i.e., reacted in situ). Similarly, in some embodiments, the compound of Formula 3 may be isolated prior to the AZ-acylation reaction. In some examples, the compound of Formula 3 may be reacted in a subsequent reaction in situ or in crude form. In some examples, the compound of Formula 3 may be reacted without isolation and / or purification (i.e., reacted in situ).

[0273] Scale-up Process

[0274] The process, as described herein, allows for the scalable synthetic pathway for the manufacture of a bicyclic glycine -proline compound of Formula 1. The process as described herein, for example when compared to the process described in international patent application W02005023815, can provide increased overall yield and purity of a compound of Formula 1 under scalable reaction conditions.

[0275] In some embodiments, the process is conducted on small-scale (e.g., scale of 20 mg to 1 gram), as would be suitable for research and development purposes. However, in some otherembodiments, the process is conducted on large-scale (e.g., scale of 1 kg to 2000 kg), as would be suitable for manufacturing purposes. The synthesis or one or more steps thereof may occur as a batch-type process.

[0276] In some embodiments, the process for the preparation of a bicyclic glycine-proline compound of Formula 1 (i.e., the cyclisation reaction) occurs with a starting material amount of a compound of Formula 2 of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg. That is, the process for preparing a bicyclic glycine-proline compound of Formula 1 occurs on at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg scale.

[0277] In some embodiments, the process for the preparation of a compound of Formula 2 (i.e., the iV-acylation reaction) occurs with a starting material amount of a compound of Formula 3 of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg. That is, the process for preparing a compound of Formula 2 occurs on at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg scale.

[0278] In some embodiments, the process for the preparation of a compound of Formula 3 occurs with a starting material amount of a compound of Formula 5 of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg. That is, the process for preparing a compound of Formula 3 occurs on at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg scale.

[0279] In some embodiments, the process for the preparation of a compound of Formula 3 occurs with a starting material amount of a compound of Formula 5a of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or atleast 5000 kg. That is, the process for preparing a compound of Formula 3 occurs on at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg scale.

[0280] In some embodiments, the process for the preparation of a compound of Formula 5 occurs with a starting material amount of a compound of Formula 6 of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg. That is, the process for preparing a compound of Formula 5 occurs on at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg scale.

[0281] In some embodiments, the process for the preparation of a compound of Formula 6 occurs with a starting material amount of a compound of Formula 7 of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg. That is, the process for preparing a compound of Formula 6 occurs on at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg scale, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg.

[0282] In some embodiments, the process provides a molar conversion of a compound of Formula 2 to a bicyclic glycine-proline compound of Formula 1 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99%, as measured by HPLC.

[0283] In some embodiments, the process provides a molar conversion of a compound of Formula 3 to a compound of Formula 2 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99%, as measured by HPLC.

[0284] In some embodiments, the process provides a molar conversion of a compound of Formula 5a to a compound of Formula 3 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99%, as measured by HPLC.In some embodiments, the process provides a molar conversion of a compound of Formula 5 to a compound of Formula 5a of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99%, as measured by HPLC.

[0285] In some embodiments, the process provides a molar conversion of a compound of Formula 6 to a compound of Formula 5 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99%, as measured by HPLC.

[0286] In some embodiments, the process provides a molar conversion of a compound of Formula 7 to a compound of Formula 6 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99%, as measured by HPLC.

[0287] In some embodiments, the process provides a yield of a bicyclic glycine-proline compound of Formula 1 of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, as determined from a compound of Formula 2 starting material. In some embodiments, the process of reacting a compound of Formula 2 to form the bicyclic glycine-proline compound of Formula 1, as described herein, can provide between about 50% and 99.5%, between about 70% and 99.5%, or between about 80% and 99.5% yield, of a bicyclic glycine-proline compound of Formula 1.

[0288] In some embodiments, the process provides a yield of a compound of Formula 2 of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, as determined from a compound of Formula 3 starting material. In some embodiments, the process of reacting a compound of Formula 3 to form the compound of Formula 2, as described herein, can provide between about 50% and 99.5%, between about 70% and 99.5%, or between about 80% and 99.5% yield, of a compound of Formula 2.

[0289] In some embodiments, the process provides a yield of a compound of Formula 3 of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, as determined from a compound of Formula 5a starting material. In some embodiments, the process of reacting a compound of Formula 5a to form the compound of Formula 3, as described herein, can provide between about 50% and 99.5%, between about 70% and 99.5%, or between about 80% and 99.5% yield, of a compound of Formula 3.In some embodiments, the process provides a yield of a compound of Formula 5a of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, as determined from a compound of Formula 5 starting material. In some embodiments, the process of reacting a compound of Formula 5 to form the compound of Formula 5a, as described herein, can provide between about 50% and 99.5%, between about 70% and 99.5%, or between about 80% and 99.5% yield, of a compound of Formula 5a.

[0290] In some embodiments, the process provides a yield of a compound of Formula 5 of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, as determined from a compound of Formula 6 starting material. In some embodiments, the process of reacting a compound of Formula 6 to form the compound of Formula 5, as described herein, can provide between about 50% and 99.5%, between about 70% and 99.5%, or between about 80% and 99.5% yield, of a compound of Formula 5.

[0291] In some embodiments, the process provides a yield of a compound of Formula 6 of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, as determined from a compound of Formula 7 starting material. In some embodiments, the process of reacting a compound of Formula 7 to form the compound of Formula 6, as described herein, can provide between about 50% and 99.5%, between about 70% and 99.5%, or between about 80% and 99.5% yield, of a compound of Formula 6.

[0292] In some embodiments, the overall process of the synthesis of a bicyclic glycine-proline compound of Formula 1 from a compound of Formula 7 (i.e., conversion of a compound of Formula 7 to Formula 6 to Formula 5 to Formula 5 a to Formula 3 to Formula 2 to Formula 1) provides an overall yield of between about 20% and about 95%, between about 30% and about 90%, between about 40% and about 85%, or between about 60% and about 80%. In one example, the process for preparing a bicyclic glycine-proline compound of Formula 1 from a compound of Formula 7 provides an overall yield of at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0293] In some embodiments, the overall process of the synthesis of a bicyclic glycine-proline compound of Formula 1 from a compound of Formula 5a (i.e., conversion of a compound of Formula 5a to Formula 3 to Formula 2 to Formula 1) provides an overall yield of between about 20% and about 95%, between about 30% and about 90%, between about 40% and about 85%, or between about 60% and about 80%. In one example, the process for preparing a bicyclicglycine-proline compound of Formula 1 from a compound of Formula 5a provides an overall yield of at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0294] In some embodiments, the overall process of the synthesis of a bicyclic glycine-proline compound of Formula 1 from a compound of Formula 3 (i.e., conversion of a compound of Formula 3 to Formula 2 to Formula 1) provides an overall yield of between about 20% and about 95%, between about 30% and about 90%, between about 40% and about 85%, or between about 60% and about 80%. In one example, the process for preparing a bicyclic glycine-proline compound of Formula 1 from a compound of Formula 3 provides an overall yield of at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0295] Compounds

[0296] In some embodiments, there is provided a bicyclic glycine-proline compound of Formula 1:

[0297]

[0298] Formula 1;

[0299] prepared by any one or more of the processes as described herein.

[0300] In some embodiments, there is provided a bicyclic glycine-proline compound of Formula 1(R):

[0301]

[0302] Formula 1(R);

[0303] prepared by any one or more of the processes described herein.

[0304] In some embodiments, there is provided a compound of Formula 2:

[0305]

[0306] Formula 2;

[0307] wherein R1and X1are as defined herein, prepared by any one or more of the processes as described herein.

[0308] In some embodiments, there is provided a compound of Formula 2(7 ):

[0309]

[0310] wherein R1and X1are as defined herein, prepared by any one or more of the processes as described herein.

[0311] In some embodiments, there is provided a compound of Formula 2a:

[0312]

[0313] Formula 2a;

[0314] prepared by any one or more of the processes described herein.

[0315] In some embodiments, there is provided a compound of Formula 2a(7?):

[0316]

[0317] Formula 2a( / ?):prepared by any one or more of the processes described herein.

[0318] In some embodiments, there is provided a compound of Formula 2b:

[0319]

[0320] Formula 2b;

[0321] prepared by any one or more of the processes described herein.

[0322] In some embodiments, there is provided a compound of Formula 2b(7?):

[0323]

[0324] Formula 2b( / ?);

[0325] prepared by any one or more of the processes described herein.

[0326] In some embodiments, there is provided a compound of Formula 2c:

[0327]

[0328] Formula 2c;

[0329] prepared by any one or more of the processes described herein.

[0330] In some embodiments, there is provided a compound of Formula 2c(7?):

[0331]

[0332] prepared by any one or more of the processes described herein.

[0333] In some embodiments, there is provided a compound of Formula 2d:

[0334]

[0335] Formula 2d;

[0336] prepared by any one or more of the processes described herein.

[0337] In some embodiments, there is provided a compound of Formula 2d(7?):

[0338]

[0339] Formula 2d( / ?);

[0340] prepared by any one or more of the processes described herein.

[0341] Compositions

[0342] Whilst a compound of Formula 1 or salt thereof may, in some embodiments, be administered alone, it is more typically administered as part of a pharmaceutical composition or formulation. Thus, the present disclosure also provides a pharmaceutical composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The pharmaceutical composition comprises one or more pharmaceutically acceptable diluents, carriers, or excipients (collectively referred to herein as “excipient” materials).

[0343] The present disclosure also provides pharmaceutical formulations or compositions, both for veterinary and for human medical use, which comprise compounds of Formula 1 of the present disclosure, or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers, and optionally any other therapeutic ingredients, stabilisers, or the like. The carrier(s) must be pharmaceutically acceptable in the sense of beingcompatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof.

[0344] The pharmaceutical formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing a compound of Formula 1, or pharmaceutically acceptable salt thereof, into association with the excipient that constitutes one or more necessary ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.

[0345] A tablet may be made for example by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active, or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be optionally coated or scored, and may be formulated so as to provide slow, pulsated or controlled release of the compound of Formula 1. The compound of Formula 1 can, for example, be administered in a form suitable for immediate release or controlled release. Immediate release or controlled release can be achieved by the use of suitable pharmaceutical compositions comprising a compound of Formula 1 or, particularly in the case of controlled release, by the use of devices such as subcutaneous implants or osmotic pumps. A compound of Formula 1 may also be administered liposomally.

[0346] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula 1 according to any embodiments or examples thereof as described herein:

[0347]

[0348] Formula 1;

[0349] wherein the compound of Formula 1 is provided in high purity, for example in a wt% of at least about 95, 96, 97, 98, 99, 99.5 or 99.9. It will be appreciated that the high purity is in relation toany impurities that might be derived during its synthesis or purification. For example, any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein. It will be appreciated that the impurities relate to the byproducts of the process and not to any pharmaceutically acceptable excipients included in a pharmaceutical composition.

[0350] In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1, wherein the compound of Formula 1 is provided in high purity, for example in a wt% of at least about 98. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1, wherein the compound of Formula 1 is provided in high purity, for example in a wt% of at least about 99. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1, wherein the compound of Formula 1 is provided in high purity, for example in a wt% of at least about 99.5. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1, wherein the compound of Formula 1 is provided in high purity, for example in a wt% of at least about 99.9. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1 (7?), wherein the compound of Formula 1(R) is provided in high purity, for example in a wt% of at least about 98. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1(R), wherein the compound of Formula 1(R) is provided in high purity, for example in a wt% of at least about 99. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1(R), wherein the compound of Formula 1(R) is provided in high purity, for example in a wt% of at least about 99.5. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1(R), wherein the compound of Formula 1(R) is provided in high purity, for example in a wt% of at least about 99.9.

[0351] In some embodiments, the process for preparing a bicyclic glycine-proline compound of Formula 1, comprising a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1, may provide a composition in which any unreacted compound ofFormula 2 remains (i.e., as an impurity). However, beneficially, the process described herein provides for a composition in which only trace amounts of a compound of Formula 2 may, in some embodiments, remain.

[0352] Accordingly, in some embodiments, there is provided a composition comprising a compound of Formula 1 according to any embodiments or examples thereof as described herein:

[0353]

[0354] Formula 1;

[0355] wherein a compound of Formula 2:

[0356]

[0357] Formula 2;

[0358] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001, wherein R1is a terminal group; and X1is a halogen. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0359] In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.05. In oneexample, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.001. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.0001. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.00001. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.000001.

[0360] In some embodiments, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0361] In some embodiments, there is provided a composition comprising a compound of Formula 1(R) according to any embodiments or examples thereof as described herein:

[0362]

[0363] Formula 1(R);

[0364] wherein a compound of Formula 2(R):

[0365]

[0366] Formula 2(R);

[0367] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001,wherein R1is a terminal group; and X1is a halogen. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0368] In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.05. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.001. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.0001. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.00001. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.000001.

[0369] In some embodiments, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.Accordingly, in some embodiments, there is provided a composition comprising a compound of Formula 1 according to any embodiments or examples thereof as described herein:

[0370]

[0371] Formula 1;

[0372] wherein a compound of Formula 2a:

[0373]

[0374] Formula 2a;

[0375] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0376] In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.05. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.001. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in anamount (weight % of the amount of the compound of Formula 1) of less than about 0.0001. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.00001. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.000001.

[0377] In some embodiments, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0378] In some embodiments, there is provided a composition comprising a compound of Formula 1(R) according to any embodiments or examples thereof as described herein:

[0379]

[0380] wherein a compound of Formula 2a(7?):

[0381]

[0382] Formula 2a( / ?):

[0383] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.05. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.001. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.0001. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.00001. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.000001.

[0384] In some embodiments, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0385] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula 1 and one or more excipients, according to any embodiments or examples thereof as described herein:

[0386]

[0387] Formula 1;

[0388] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0389] In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 1. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.5. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.1. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.05. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1(R), wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 1. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1(R), wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.5. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1(R), wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1(R), wherein anyimpurities, if present, are in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.05.

[0390] Accordingly, in some embodiments, there is provided a composition comprising a compound of Formula 1 and one or more excipients according to any embodiments or examples thereof as described herein:

[0391]

[0392] Formula 1;

[0393] wherein a compound of Formula 2:

[0394]

[0395] Formula 2;

[0396] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001, wherein R1is a terminal group; and X1is a halogen. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0397] In one example, there is provided a composition comprising a compound of Formula 1 and one or more excipients, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1 and one or more excipients, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1 and one or more excipients, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1 and one or more excipients, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1)of less than about 0.05. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.001. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.0001. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.00001. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.000001.

[0398] In some embodiments, there is provided a composition comprising a compound of Formula 1 and one or more excipients, wherein a compound of Formula 2, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1 and one or more excipients, wherein a compound of Formula 2, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0399] In some embodiments, there is provided a composition comprising a compound of Formula 1(R) according to any embodiments or examples thereof as described herein:

[0400]

[0401] wherein a compound of Formula 2(R):

[0402]

[0403] Formula 2(R);if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001, wherein R1is a terminal group; and X1is a halogen. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0404] In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.05. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.001. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.0001. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.00001. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.000001.

[0405] In some embodiments, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2(R), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.Accordingly, in some embodiments, there is provided a composition comprising a compound of Formula 1 and one or more excipients according to any embodiments or examples thereof as described herein:

[0406]

[0407] Formula 1;

[0408] wherein a compound of Formula 2a:

[0409]

[0410] Formula 2a;

[0411] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, 0.000001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0412] In one example, there is provided a composition comprising a compound of Formula 1 and one or more excipients, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1 and one or more excipients, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1 and one or more excipients, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1 and one or more excipients, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.05. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1 of less than about 0.001. In one example, thereis provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.0001. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.00001. In one example, there is provided a composition comprising a compound of Formula 1, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.000001.

[0413] In some embodiments, there is provided a composition comprising a compound of Formula 1 and one or more excipients, wherein a compound of Formula 2a, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1 and one or more excipients, wherein a compound of Formula 2a, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0414] In some embodiments, there is provided a composition comprising a compound of Formula 1(R) according to any embodiments or examples thereof as described herein:

[0415]

[0416] Formula 1(R);

[0417] wherein a compound of Formula 2a(7?):

[0418]

[0419] Formula 2a(7?);

[0420] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001. The composition may be a pharmaceutical composition comprising one or morepharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0421] In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.05. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.001. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.0001. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.00001. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.000001.

[0422] In some embodiments, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 2a(7?), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0423] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula 1 according to any embodiments or examples thereof as described herein:

[0424]

[0425] Formula 1;

[0426] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. In some embodiments, the impurities are selected from the group consisting of:

[0427]

[0428] Impurity g; Impurity h; Impurity i;

[0429]

[0430] Impurity j; Impurity k; Impurity l; and

[0431]

[0432] Impurity m.

[0433] It will be appreciated that Impurity j and Impurity k may be difficult to distinguish from one another. Accordingly, in some embodiments, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1 according to any embodiments or examples thereof as described herein, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001, and wherein the impurities are a combination of Impurity j and Impurity k.

[0434] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula 1 and one or more excipients according to any embodiments or examples thereof as described herein:

[0435]

[0436] Formula 1;

[0437] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. In some embodiments, the impurities are selected from the group consisting of:

[0438]

[0439] Impurity j; Impurity k; Impurity l; and

[0440]

[0441] Impurity m.

[0442] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula 1(R) according to any embodiments or examples thereof as described herein:

[0443]

[0444] Formula 1(R);

[0445] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. In some embodiments, the impurities are selected from the group consisting of:

[0446]

[0447]

[0448] Impurity g(R); Impurity h(7?); Impurity i(7?);

[0449]

[0450] Impurity m(7?); and Formula 1(5).

[0451] It will be appreciated that Impurity j (7?) and Impurity k(7?) may be difficult to distinguish from one another. Accordingly, in some embodiments, there is provided a composition comprising a bicyclic glycine -proline compound of Formula 1(R) according to any embodiments or examples thereof as described herein, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001, and wherein the impurities are a combination of Impurity j(7?) and Impurity k(7?).

[0452] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula 1(R) and one or more excipients according to any embodiments or examples thereof as described herein:

[0453]

[0454] Formula 1(R);

[0455] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. In some embodiments, the impurities are selected from the group consisting of:

[0456]

[0457]

[0458] Impurity i( / f);

[0459]

[0460]

[0461] Impurity j( / ?); Impurity!( / ?);

[0462]

[0463]

[0464] Impurity m( / f); and Formula 1(S).

[0465] It will be appreciated that, in the process for preparing a compound of Formula 1(R), the corresponding S-enantiomer, being a compound of Formula 1(5), may, in someembodiments, be provided in the process. The presence of Formula 1(5) in a composition comprising a compound of Formula 1 (7?), may be considered an impurity. This impurity may arise, for example, due to the presence of (S)-allylproline impurity in the (A’)-al lydprolinc starting material, which may be carried through the process described herein. Accordingly, in some embodiments, it is desirable to minimise the amount of a compound of Formula 1(5) in a composition comprising a compound of Formula 1(R). It is typically difficult to separate enantiomers, particularly on large-scale and throughout commercial production. Beneficially, the process described herein provides for, in some embodiments, a composition comprising only trace amounts of a compound of Formula 1(5).

[0466] Accordingly, in some embodiments, there is provided a composition comprising a compound of Formula 1(R) according to any embodiments or examples thereof as described herein:

[0467]

[0468] Formula 1(R);

[0469] wherein a compound of Formula 1(5):

[0470]

[0471] Formula l(. S'):

[0472] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0473] In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 1 (. S'), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 1(5), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of lessthan about 0.5. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 1(5), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 1(5), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.05.

[0474] In some embodiments, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 1(5), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1(R), wherein a compound of Formula 1(5), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0475] In some embodiments, there is provided a composition comprising a compound of Formula 1(R) and one or more excipients according to any embodiments or examples thereof as described herein:

[0476]

[0477] Formula 1(R);

[0478] wherein a compound of Formula 1(5):

[0479]

[0480] Formula 1(5):

[0481] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.In one example, there is provided a composition comprising a compound of Formula 1(R) and one or more excipients, wherein a compound of Formula 1(5), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1(R) and one or more excipients, wherein a compound of Formula 1(5'), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1(R) and one or more excipients, wherein a compound of Formula 1(5), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1(R) and one or more excipients, wherein a compound of Formula 1(5), if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.05.

[0482] In some embodiments, there is provided a composition comprising a compound of Formula 1(R) and one or more excipients, wherein a compound of Formula 1(5), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1(R) and one or more excipients, wherein a compound of Formula 1(5), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0483] In some embodiments, there is provided a composition comprising a compound of Formula 1 according to any embodiments or examples thereof as described herein:

[0484]

[0485] Formula 1;

[0486] wherein Impurity b:

[0487]

[0488] Impurity b;

[0489] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0490] In some embodiments, there is provided a composition comprising a compound of Formula 1 and one or more excipients according to any embodiments or examples thereof as described herein:

[0491]

[0492] Formula 1;

[0493] wherein Impurity b:

[0494]

[0495] Impurity b;

[0496] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0497] In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity b, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity b, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity b, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1, whereinImpurity b, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.05.

[0498] In some embodiments, there is provided a composition comprising a compound of Formula 1 according to any embodiments or examples thereof as described herein:

[0499]

[0500] Formula 1;

[0501] wherein Impurity c:

[0502]

[0503] Impurity c;

[0504] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0505] In some embodiments, there is provided a composition comprising a compound of Formula 1 and one or more excipients according to any embodiments or examples thereof as described herein:

[0506]

[0507] Formula 1;

[0508] wherein Impurity c:

[0509]

[0510] Impurity c;

[0511] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0512] In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity c, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity c, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity c, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity c, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.05.

[0513] In some embodiments, there is provided a composition comprising a compound of Formula 1 according to any embodiments or examples thereof as described herein:

[0514]

[0515] Formula 1;

[0516] wherein Impurity g:

[0517]

[0518] Impurity g;

[0519] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0520] In some embodiments, there is provided a composition comprising a compound of Formula 1 and one or more excipients according to any embodiments or examples thereof as described herein:

[0521]

[0522] Formula 1;

[0523] wherein Impurity g:

[0524]

[0525] Impurity g;

[0526] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0527] In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity g, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity g, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity g, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.3. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity g, if present, is in an amount (weight % of the amount of the compound of Formula 1)of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity g, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.05.

[0528] In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity g, if present is in an amount (weight % of the amount of the compound of Formula 1) of between about 0.0001 and about 1.0. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity g, if present is in an amount (weight % of the amount of the compound of Formula 1) of between about 0.0001 and about 0.1. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity g, if present is in an amount (weight % of the amount of the compound of Formula 1) of between about 0.05 and about 0.07.

[0529] It has been surprisingly found that, in some embodiments, Impurity g may form during the process for preparing a bicyclic glycine -proline compound of Formula 1, as described herein. In particular, the cyclisation reaction of synthesized α-2-haloacetylpyrrolidines 2a and 2b into the target compound of Formula 1, using methanolic ammonia, has been surprisingly found to, in some embodiments, result in the formation of Impurity g.

[0530] It has also been surprisingly found that, in some embodiments, hydrolysis of a bicyclic glycine-proline compound of Formula 1 results in the formation of Impurity g. This may be particularly the case under basic conditions. In some embodiments, the formation of Impurity g occurs when a bicyclic glycine-proline compound of Formula 1 is subjected to basic conditions, for example, a pH value of between about 7.5 and about 12, between about 7.5 and about 10, or between about 7.5 and about 9.0.

[0531] It has also been surprisingly found that, in some embodiments, Impurity g may form during shelf-storage of a composition comprising a bicyclic glycine-proline compound of Formula 1 (e.g., drug product). Shelf-storage includes, in some embodiments, storage at room temperature for a period of at least about 12 months, at least about 24 months, at least about 36 months, or at least about 60 months. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1, wherein the composition has been subjected to about 36 months or less of shelf- storage, and Impurity g, is present in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.1. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1, wherein the composition has been subjected to about 60 months or less of shelf-storage, and Impurity g, is present in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.1.

[0532] In some embodiments, there is provided a composition comprising a compound of Formula 1 according to any embodiments or examples thereof as described herein:

[0533]

[0534] Formula 1;

[0535] wherein Impurity h:

[0536]

[0537] Impurity h;

[0538] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0539] In some embodiments, there is provided a composition comprising a compound of Formula 1 and one or more excipients according to any embodiments or examples thereof as described herein:

[0540]

[0541] Formula 1;

[0542] wherein Impurity h:

[0543]

[0544] Impurity h;

[0545] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0546] In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity h, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity h, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity h, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity h, if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.05.

[0547] In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity h, if present is in an amount (weight % of the amount of the compound of Formula 1) of between about 0.0001 and about 1.0. In one example, there is provided a composition comprising a compound of Formula 1, wherein Impurity h, if present is in an amount (weight % of the amount of the compound of Formula 1) of between about 0.0001 and about 0.1.

[0548] It has been surprisingly found that, in some embodiments, Impurity h may form during the process for preparing a bicyclic glycine -proline compound of Formula 1, as described herein.

[0549] It has also been surprisingly found that, in some embodiments, Impurity h may form during shelf-storage of a composition comprising a bicyclic glycine -proline compound of Formula 1 (e.g., drug product). Shelf-storage includes, in some embodiments, storage at room temperature for a period of at least about 12 months, at least about 24 months, at least about 36months, or at least about 60 months. In one example, there is provided a composition comprising a bicyclic glycine -proline compound of Formula 1, wherein the composition has been subjected to about 36 months or less of shelf- storage, and Impurity h, is present in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.1 or less than about 0.05. In one example, there is provided a composition comprising a bicyclic glycineproline compound of Formula 1, wherein the composition has been subjected to about 60 months or less of shelf-storage, and Impurity h, is present in an amount (weight % of the amount of the compound of Formula 1) of less than about 0.1 or less than about 0.05.

[0550] In some embodiments, there is provided a composition comprising a compound of Formula 1(R) according to any embodiments or examples thereof as described herein:

[0551]

[0552] Formula 1(R);

[0553] wherein Impurity b(R):

[0554]

[0555] Impurity b(R);

[0556] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0557] The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0558] In some embodiments, there is provided a composition comprising a compound of Formula 1(R) and one or more excipients according to any embodiments or examples thereof as described herein:

[0559]

[0560] Formula 1(R);

[0561] wherein Impurity b(R):

[0562]

[0563] Impurity b(R);

[0564] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0565] In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity b(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity b(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity b(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity b(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.05.

[0566] The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0567] In some embodiments, there is provided a composition comprising a compound of Formula 1(R) according to any embodiments or examples thereof as described herein:

[0568]

[0569] wherein Impurity c(R):

[0570]

[0571] Impurity c(R);

[0572] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0573] The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein. In some embodiments, there is provided a composition comprising a compound of Formula 1(R) and one or more excipients according to any embodiments or examples thereof as described herein:

[0574]

[0575] Formula 1(R);

[0576] wherein Impurity c(R):

[0577]

[0578] Impurity c(R);if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0579] In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity c(R):, if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity c(R):, if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity c(R):, if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity c(R):, if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.05.

[0580] The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0581] In some embodiments, there is provided a composition comprising a compound of Formula 1(R) according to any embodiments or examples thereof as described herein:

[0582]

[0583] Formula 1(R);

[0584] wherein Impurity g(R)::

[0585]

[0586] Impurity g(R);

[0587] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The compositionmay be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0588] In some embodiments, there is provided a composition comprising a compound of Formula 1(R) and one or more excipients according to any embodiments or examples thereof as described herein:

[0589]

[0590] Formula 1(R);

[0591] wherein Impurity g(R):

[0592]

[0593] Impurity g(R);

[0594] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0595] In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity g(R):, if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity g(R):, if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity g(R):, if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.3. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity g(R):, if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1(R), whereinImpurity g(R), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.05.

[0596] In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity g(R):, if present is in an amount (weight % of the amount of the compound of Formula 1(R)) of between about 0.0001 and about 1.0. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity g(R):, if present is in an amount (weight % of the amount of the compound of Formula 1(R)) of between about 0.0001 and about 0.1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity g(R):, if present is in an amount (weight % of the amount of the compound of Formula 1(R)) of between about 0.05 and about 0.07.

[0597] It has been surprisingly found that, in some embodiments, Impurity g(R) may form during the process for preparing a bicyclic glycine -proline compound of Formula 1(R), as described herein. In particular, the cyclisation reaction of synthesized N-(2-haloacetyl)pyrrolidines 2a(7?) and 2b(7?) into the target compound of Formula 1(R), using methanolic ammonia, has been surprisingly found to, in some embodiments, result in the formation of Impurity g(R).

[0598] It has also been surprisingly found that, in some embodiments, hydrolysis of a bicyclic glycine-proline compound of Formula 1(R) results in the formation of Impurity g(R). This may be particularly the case under basic conditions. In some embodiments, the formation of Impurity g(R) occurs when a bicyclic glycine-proline compound of Formula 1(R) is subjected to basic conditions, for example, a pH value of between about 7.5 and about 12, between about 7.5 and about 10, or between about 7.5 and about 9.0.

[0599] It has also been surprisingly found that, in some embodiments, Impurity g(R) may form during shelf-storage of a composition comprising a bicyclic glycine-proline compound of Formula 1(R) (e.g., drug product). Shelf-storage includes, in some embodiments, storage at room temperature for a period of at least about 12 months, at least about 24 months, at least about 36 months, or at least about 60 months. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1(R), wherein the composition has been subjected to about 36 months or less of shelf- storage, and Impurity g(R), is present in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1(R), wherein the composition has been subjected to about 60 months or less ofshelf- storage, and Impurity g(R), is present in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1.

[0600] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula 1(R) according to any embodiments or examples thereof as described herein:

[0601]

[0602] Impurity h(7?);

[0603] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0604] In some embodiments, there is provided a composition comprising a compound of Formula 1(R) and one or more excipients according to any embodiments or examples thereof as described herein:

[0605]

[0606] Formula 1(R);

[0607] wherein Impurity h(7?):

[0608]

[0609] Impurity h(R):

[0610] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0611] In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity h(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity h(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity h(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity h(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 0.05.

[0612] In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity h(7?), if present is in an amount (weight % of the amount of the compound of Formula 1(R)) of between about 0.0001 and about 1.0. In one example, there is provided a composition comprising a compound of Formula 1(R), wherein Impurity h(7?), if present is in an amount (weight % of the amount of the compound of Formula 1(R)) of between about 0.0001 and about 0.1.

[0613] In some embodiments, there is provided a composition comprising a compound of Formula 2a according to any embodiments or examples thereof as described herein:

[0614]

[0615] Formula 2a;wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0616] In some embodiments, there is provided a composition comprising a compound of Formula 2a and one or more excipients according to any embodiments or examples thereof as described herein:

[0617]

[0618] Formula 2a;

[0619] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0620] In one example, there is provided a composition comprising a compound of Formula 2a, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 2a, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 2a, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a) of less than about 0.1.

[0621] In some embodiments, there is provided a composition comprising a compound of Formula 2a(7 ) according to any embodiments or examples thereof as described herein:

[0622]

[0623] Formula 2a( / ?);

[0624] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. In some embodiments, the impurities are selected from the group consisting of:

[0625]

[0626] Impurity la( / ?); Impurity ma( / ?); and Impurity na( / ?).

[0627] In some embodiments, there is provided a composition comprising a compound of Formula 2a(7?) and one or more excipients according to any embodiments or examples thereof as described herein:

[0628]

[0629] Formula 2a( / ?);

[0630] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. In some embodiments, the impurities are selected from the group consisting of:

[0631]

[0632] In some embodiments, there is provided a composition comprising a compound of Formula 2a according to any embodiments or examples thereof as described herein:

[0633]

[0634] Formula 2a;

[0635] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0636] In some embodiments, there is provided a composition comprising a compound of Formula 2a and one or more excipients according to any embodiments or examples thereof as described herein:

[0637]

[0638] Formula 2a;wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0639] In some embodiments, there is provided a composition comprising a compound of Formula 2b according to any embodiments or examples thereof as described herein:

[0640]

[0641] Formula 2b;

[0642] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2b) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0643] In some embodiments, there is provided a composition comprising a compound of Formula 2b and one or more excipients according to any embodiments or examples thereof as described herein:

[0644]

[0645] Formula 2b;

[0646] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2b) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0647] In some embodiments, there is provided a composition comprising a compound of Formula 2c according to any embodiments or examples thereof as described herein:

[0648]

[0649] Formula 2c;

[0650] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2c) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0651] In some embodiments, there is provided a composition comprising a compound of Formula 2c and one or more excipients according to any embodiments or examples thereof as described herein:

[0652]

[0653] Formula 2c;

[0654] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2c) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may beselected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0655] In some embodiments, there is provided a composition comprising a compound of Formula 2d according to any embodiments or examples thereof as described herein:

[0656]

[0657] Formula 2d;

[0658] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2d) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0659] In some embodiments, there is provided a composition comprising a compound of Formula 2d and one or more excipients according to any embodiments or examples thereof as described herein:

[0660]

[0661] Formula 2d;

[0662] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2d) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or morepharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0663] The present disclosure will now be described with reference to the following examples which illustrate some particular aspects of the present disclosure. However, it is to be understood that the particularity of the following description of the present disclosure is not to supersede the generality of the preceding description of the present disclosure.

[0664] Examples

[0665] The present disclosure is further illustrated by the following examples. These examples are offered by way of illustration only and are not intended to limit the scope of the disclosure.

[0666] Overall Synthesis

[0667] A non-limiting illustration of the overall synthesis used to obtain the bicyclic glycineproline compound of Formula 1(R) is provided in Scheme 4.

[0668]

[0669] Formula 1(R) Formula 5a Formula 3(R) Formula 2(R) cG-2-AllylP

[0670] Scheme 4. Overall synthesis of Formula 1(R).

[0671] The pyrrolidine-2-carboxylate 3a(7?) was prepared as freebase form by methylation of commercial a-allyl-L-proline hydrochloride 5a under standard reaction conditions (SOCl₂,MeOH). Moreover, the proline methyl ester 3a( / ?) is commercially available as its HC1 salt (CAS# 112348-46-6), and 2 g of material were also used in this study.

[0672] Example 1: Step 5

[0673] The cyclisation reaction of synthesized A-(2-haloacetyl)pyrrolidines 2a( / ?) and 2b( / ?) into the target compound of Formula 1(R) was investigated using methanolic ammonia.

[0674] Preliminary test experiments were performed on a 100 mg scale in 8 mL screw-cap sealed glass vials with magnetic stirring. Compounds 2a( / ?) and 2b( / ?) were separately dissolved in the designated ammonia solutions (e.g. 7 N ammonia in MeOH, 10 equiv) and stirred at room temperature. Reaction progress was monitored by HPLC (XBridge-C18_05-80_Phos, 195 nm) at four time points: 1 h (si), 5 h (s2), ca. 20 h (s3), and 4 days (s4). The results are discussed herein.

[0675] Cyclisation Reaction of 2a

[0676]

[0677] Protocols using 7 N ammonia in MeOH (at RT or 30 °C) were compared with lower ammonia concentration conditions (4 N ammonia in MeOH, and 2 N ammonia in MeOH). The effect of alternative solvents, such as ethanol and isopropanol on cyclization of 2a( / ?), was also examined.

[0678] The results of the cyclisation reaction of A-(2-chloroacetyl)pyrrolidine-2-carboxylate 2a( / ?) with ammonia are summarised in Table 1.

[0679]

[0680] Impurity a( / ?) Impurity b( / ?) Impurity c(R) Figure 1. Impurity identification from Table 1.

[0681] Observations

[0682] The reaction of compound 2a( / ?) with 7 N ammonia in MeOH (10 equiv) at room temperature (entry 1; Modified “Reaction Conditions A / B”) afforded the desired bicyclic system 1(R) as major product (96.64 area% by HPLC). Complete conversion was observedwithin ca. 20 h, with only a single impurity already present in the substrate detected in a clean HPLC impurity profile.

[0683] Effect of ammonia: reducing the ammonia concentration to 4 N (10 equiv; entry 2; Modified “Reaction Conditions D”) and 2 N (10 equiv; entry 3; “Reaction Conditions C”) resulted in slower conversion, requiring more than 20 h for completion.

[0684] Effect of solvent: reaction of 2a( / ?) with 2 N ammonia in ethanol (10 equiv; entry 4) initially led to transesterification, forming the ethyl ester derivative 27 after 1 h at RT. The cyclization of the ethyl ester derivative 27 was significantly slower than that of the methyl ester 2a( / ?) (e.g. entry 3), yielding only 30.91 area% of 1(R) after 4 days. The use of 2 N ammonia in isopropanol (10 equiv; entry 5) resulted in a faster conversion rate than in methanol at the same ammonia concentration (entry 3), completed within 4 days at RT.

[0685] Effect of temperature: using 7 N ammonia in MeOH (10 equiv), the reaction at 30 °C (entry 7; “Reaction Conditions B”) accelerated the conversion compared to room temperature (entry 1), with comparable yields and impurity profiles.

[0686] Effect of substrate concentration / ammonia amount: substrate concentration had a minor effect on the cyclisation rate. Increasing the ammonia solution to 20 equiv (half dilution, entry 8; “Reaction Conditions A”) or decreasing it to 5 equiv (double concentration, entry 9; “Reaction Conditions D”) produced similar results to the reference experiments using 10 equiv of 7 N and 4 N ammonia in MeOH, respectively (entries 1 and 2).

[0687] Summary

[0688] In summary, 2a( / ?) treated with 7 N ammonia in MeOH (10 equiv) at 30 °C for ca. 20 h (entry 6), was the most effective for the synthesis of 1(R), achieving the highest conversion and purity (98.6 area% by HPLC). In addition, comparable results (98.9 area% 1( / ?)) were obtained under the “Reaction Conditions A” using the same ammonia solution at room temperature (7 N ammonia in MeOH, 20 equiv; entry 7). All conditions tested showed a similar impurity profile, except when ethanolic ammonia was used (entry 4).

[0689] Cyclisation Reaction of 2b

[0690]

[0691] The results of the cyclisation reaction of A-(2-bromoacetyl)pyrrolidine-2-carboxylate 2b( / ?) with methanolic ammonia are summarised in Table 2.

[0692]

[0693] Impurity a( / ?) Impurity d( / ?) Impurity c( / ?) Impurity e( / ?) Figure 2. Impurity identification from Table 2.

[0694] Observations

[0695] The cyclisation reaction of 2b( / ?) with 7 N methanolic ammonia (10 equiv) at RT (entry 1; Modified “Reaction Conditions A / B”) afforded the desired Compound 1(R) as major product (82 area%). Minor oligomeric side -products (33-35, tentatively assigned to overalkylated amines) were also observed. Complete consumption of 2b( / ?) occurred within 1 hour, with prolonged reaction times showing no significant changes except for the gradual conversion of impurity 33 into 34.

[0696] Effect of ammonia concentration: reducing the ammonia concentration to 4 N (10 equiv; entry 2; Modified “Reaction Conditions D”) and 2 N (10 equiv; entry 3; “Reaction Conditions C”) increased the yield of Compound 1(R) to 91 area% and 96 area%, respectively, while reducing the levels of impurities 33-35 compared to the reference experiment using 7 N ammonia in MeOH (entry 1). By using lower-concentration ammonia solutions, the reaction was performed under more diluted conditions, which prevents oligomerization and favours intramolecular cyclization.

[0697] Effect of temperature: performing the cyclisation reaction with 7 N ammonia in MeOH (10 equiv) at 30 °C (entry 4; “Reaction Conditions B”) resulted in comparable yields (82 area% of Compound 1( / ?)) and impurity profiles to those obtained at room temperature (entry 1).

[0698] Effect of substrate concentration / ammonia amount: diluting the reaction (half dilution) by increasing the amount of 7 N ammonia in MeOH to 20 equiv (entry 5; “Reaction Conditions A”) resulted in a higher yield of Compound 1(R) (~90 area%) and reduced levels of the oligomeric side-product 33-35 (9-10 combined area%) compared to the reference experiment using 10 equiv (entry 1). In contrast, concentrating the reaction (double concentration) by reducing the amount of 4 N ammonia in MeOH to 5 equiv (entry 6; “Reaction Conditions D”)led to a lower yield of Compound 1( / ?) (~83 area%) and higher levels of the oligomeric sideproduct (15-16 combined area%) compared to the reaction with 10 equiv (entry 2).

[0699] Summary

[0700] In summary, the treatment of 2b( / ?) under “Reaction Conditions C” (2 N NHs in MeOH, 10 equiv, RT, 5 h) provided the highest yield and purity of Compound 1 (96.5 area% by HPLC). These higher dilution conditions promote intramolecular lactam cyclization, thereby minimizing unwanted intermolecular oligomerization.

[0701] Example 2: Step 4 (Part A)

[0702] A-acylation of the synthesised pyrrolidine-2-carboxylate 3a( / ?) (freebase), along with the commercial hydrochloride salt of 3a( / ?), were examined using bromoacetyl bromide and chloroacetyl chloride as alternative acylating agents under both “Reaction Conditions A” (2 M K2CO3 / CH2CI2) and “Reaction Conditions B” (2 M K2CO3 / 2-MeTHF). Preliminary test experiments were performed on a 100 mg scale. Reaction progress was monitored by LCMS / HPLC after 1 hour at 0 °C (si), another hour at RT (s2) and ca. 18 h at RT (s3). The results are summarised in Tables 3a and 3b.

[0703]

[0704] Impurity a( / ?)

[0705] Figure 3. Impurity identification from Tables 3a and 3b.

[0706] Observations: -acylation reaction under “Reaction Conditions A” (2 M K2CO3 / CH2CI2, 1:1 v / v; entries 1-4, Table 3a)

[0707] In all cases, nearly complete conversion was achieved after 1 hour at 0 °C, with no significant changes observed when the reaction was extended for an additional hour at room temperature (RT).

[0708] Observations: - acylal ion reaction under “Reaction Conditions B” (2 M K2COs / 2-MeTHF, 1:1 v / v; entries 5-8, Table 3b)Lower conversion rates were noted compared to “Reaction Conditions A” in CH2CI2 (entries 1-4). Additional amounts of the acylating reagent should be added at 0 °C to drive the reactions to completion. When bromoacetyl bromide was used as acylating agent (entries 5 and 7), lower conversion rates and increased impurity levels were observed, even after 1 h at 0 °C, compared to reactions with chloroacetyl chloride (entries 6 and 8). The bromoacetamide product 2b( / ?) exhibited notable degradation after extended reaction times at RT (ca. 18 h), whereas the chloroacetamide derivative 2a( / ?) remained stable under similar conditions. To prevent degradation, reactions involving bromoacetyl bromide should be performed strictly at 0 °C under controlled conditions.

[0709] Overall Observations

[0710] Comparable results were obtained for the pyrrolidine-2-carboxylate 3a( / ?) used either as freebase (entries 3-4 and 7-8) or as HC1 salt (entries 1-2 and 5-6) under both reaction conditions.

[0711] Overall, the 2-chloroacetamide 2a( / ?) demonstrated greater stability than the 2-bromoacetamides 2b( / ?) under acylation conditions, especially at RT, where the latter degraded more readily due to their higher reactivity.

[0712] CH2CI2 proved to be a more favourable solvent than 2-MeTHF.

[0713] In addition, the “Reaction Conditions A” facilitated product isolation with improved yield and purity.

[0714] Summary

[0715] In conclusion, A-acylation of the pyrrolidine-2-carboxylate 3a( / ?) (HC1 salt or freebase) with chloroacetyl chloride in CH2CI2 at 0 °C (entries 2 and 4; “Reaction Conditions A”) produced the best results in terms of conversion, purity, and product stability.

[0716] Example 3: Step 4 (Part B)

[0717] Further analysis of the A-acylation reaction was undertaken using “Reaction Conditions C” and “Reaction Conditions D”. Specifically, the A-acylation rection of the pyrrolidine 3a( / ?) was examined under conditions using bromoacetyl bromide as the acylating agent. The results are summarised in Table 4.

[0718]

[0719] Figure 4. Impurity identification from Table 4.

[0720] Observations

[0721] The reaction of pyrrolidine 3a( / ?)*HCl under “Reaction Conditions C” using bromoacetyl bromide and triethylamine in chloroform (entry 1) afforded the desired bromoacetamide 2b( / ?), but with lower yields and purities than the standard aqueous / organic biphasic solvent system employed in “Reaction Conditions A” (entry 4) or “Reaction Conditions B” (entry 5). Moreover, these homogeneous reaction conditions introduced additional product-related impurities as detected by HPLC / LCMS and resulted in variable amounts of triethylammonium halide as a by-product in the isolated material.

[0722] When pyrrolidine-2-carboxylate 3a( / ?) was reacted under “Reaction Conditions C” using chloroacetyl chloride as the acylating agent (entry 3), the chloroacetamide 2a( / ?) was isolated with yields comparable to those obtained under “Reaction Conditions A” (entry 4) or “Reaction Conditions B” (entry 5). However, the purity was lower, with multiple minor impurities and residual triethylamine hydrochloride (TEA- HC1) present.

[0723] A-acylation of pyrrolidine 3a( / ?) under “Reaction Conditions D” of entries 1-2 produced results similar to those obtained under “Reaction Conditions B” (entry 4). The target acylated product 2b( / ?) was isolated in high yield and purity (entry 2). The “Reaction Conditions D” and “Reaction Conditions A” protocols are quite similar, both using aqueous potassium carbonate as base in CH2CI2, with the main differences lying in reagent stoichiometry and reaction concentration.

[0724] In summary, neither “Reaction Condition C” nor “Reaction Condition D” provided significant improvements over the “Reaction Conditions A” procedure for the A-acylation of pyrrolidine 3a( / ?).

[0725] Example 4: Step 4 (Base Screen of “Reaction Conditions A”)

[0726] The A-acylation reaction of the pyrrolidine-2-carboxylate 3a( / ?) with chloroacetyl chloride was evaluated under various conditions to explore alternatives to the standard“Reaction Conditions A” protocol using aqueous K2CO3. Table 5 summarises the results of these experiments, which tested reactions with no base (entry 2), in a biphasic aqueous system without base (entry 3), and in the presence of various inorganic and organic bases, including K3PO4 (entry 4), Na2CO3(entry 5), KHCO3 (entry 6), K2HPO4 (entry 7), NaHCO3(entry 8), EtsN (entry 9), DIPEA (entry 10) and DBU (entry 11).

[0727] Observations

[0728] In the absence of a base (entry 2) or in a biphasic system with water only (entry 3), the desired chloro acetamide 2a( / ?) was formed as the major product (90 area% by HPLC). However, incomplete conversion was observed, with 7-9% of unreacted starting material remaining. Importantly, no acid hydrolysis occurred and the impurity profile remained clean, comparable to the reference reaction with K2CO3 (entry 1).

[0729] Aqueous solutions of alternative inorganic bases (entries 4-8) did not significantly improve the reaction outcomes. The use of K2CO3 (entry 1), K3PO4 (entry 4), KHCO3 (entry 6), and K2HPO4 (entry 7) resulted in clear biphasic mixtures that led to 2a( / ?) with comparable yield and purity. Reactions with NaiCCE (entry 5) and NaHCOs (entry 8) formed biphasic suspensions and produced 2a( / ?) with impurity profiles similar to the reference experiment (entry 1), although traces of unreacted starting material remained.

[0730] Reactions with organic bases (entries 9-11), which formed monophasic mixtures in CH2CI2, resulted in lower conversion rates and introduced additional minor side -products. Among these, only EtsN (entry 9) provided a comparable yield (94%) of 2a( / ?), albeit with a more complex impurity profile.

[0731] Summary

[0732] In summary, none of the tested bases offered significant advantages over aqueous K2CO3, which (along with K3PO4, K2HPO4 and KHCO3) remained the most effective in achieving high-purity results.Table 1. Cyclisation reaction of 2V-(2-chloroacetyl)pyrrolidine-2-carboxylate 2a( / ?) with ammonia.

[0733]

[0734]

[0735]

[0736] Abbreviations: n.d. = not determined (product was not isolated).aPeak area measurement by manual integration (195 nm).bHPLC monitoring a (si), 5 h (s2), ca. 20 h (s3) and 4 days (s4) at RT.cN-acylated pyrrolidine 2a(R) was contaminated with a minor product-related impurity.dFormation of a white precipitate was observed after ca. 20 h at RT (s3)Table 2. Cyclisation reaction of N-(2-bromoacetyl)pyrrolidine-2-carboxylate 2b(R) with ammonia.

[0737]

[0738] 101

[0739]

[0740] Abbreviations: n.d. = not determined (product was not isolated).aPeak area measurement by manual integration (195 nm).bHPLC monitoring a (si), 5 h (s2), ca. 20 h (s3) and 4 days (s4) at RT.cA-acylatcd pyrrolidine 2b( / ?) containing traces of impurity.dFormation of a white precipitate erved after ca. 20 h at RT (s3).Table 3a. A-acylation reaction of pyrrolidine-2-carboxylate 3a( / ?) with dihalide 4 (“Reaction conditions A”).

[0741]

[0742]

[0743] ak area measurement by manual integration (210 nm).bHPLC monitoring after 1 hour at 0°C (si), an additional hour at RT (s2) and overnight stirrin (ca. 18 h, s3).cOverlapping of the starting material 3a( / ?) and another unknown impurity.

[0744] Table 3b. A-acylation reaction of pyrrolidine-2-carboxylate 3a( / ?) with dihalide 4 (“Reaction conditions B”).

[0745]

[0746] \

[0747]

[0748] aPeak area measurement by manual integration (210 nm).bHPLC monitoring after 1 hour at 0°C (si), an additional hour at RT (s2) and overn ring at RT (ca. 18 h, s3)dOverlapping of the starting material 3a( / ?) and another unknown impurity.eThe crude material contained BHT (5-7 area% LC; approx. 3-5 wt% by NMR) and residual 2-MeTHF (approx. 2-6 wt% by NMR).

[0749] Table 4. AZ-acylalion reaction of pyrrolidine 3a( / ?).

[0750]

[0751]

[0752] aPeak area measurement by manual integration (210 nm).bHPLC monitoring after 1 hour (si) at -10 °C (entry 1) or 0°C (entries 2-5). The react e quenched after an additional hour under these conditions.cPyrrolidine 3a( / ?) used as freebase form was contaminated with a minor unidentified impu 2 min, m / z 184 [M+H]+).dThe crude material contained a variable amount of triethylammonium halide (detected by NMR).eThe crude material conta T (5-7 area% by HPLC; approx. 3-5 wt% by NMR) and residual 2-MeTHF (approx. 2-6 wt% by NMR).

[0753] Table 5. Base screen of A-acylalion reaction of pyrrolidine 3a( / ?) with chloroacetyl chloride using “Reaction Conditions A”.

[0754]

[0755]

[0756] ak area measurement by manual integration (210 nm).bHPLC monitoring after 1 hour at 0°C (si), an additional hour at RT (s2) and overnight stirrin (ca. 18 h, s3).cPyrrolidine 3a( / ?) used as freebase form was contaminated with a minor unidentified impurity (3.12 min, m / z 184 [M+H]+).dpH va asured using universal indicator paper from Sigma- Aldrich.eThe impurity, initially present in the starting material 3a( / ?), was consistently detected i tion mixtures by HPLC analysis (0.5-1.0 area%).Example 5: Overall Conclusions Regarding Step 5 and Step 4

[0757] The cyclisation reaction (Step 5) and A-acylation reaction (Step 4) were thoroughly investigated in Examples 1-4 herein, and the key conclusions drawn are summarised below. Preparation of Compounds 2b(R) / 2a(R) (Step 4)

[0758] The A-acylation of pyrrolidine 3a( / ?) was investigated under various conditions using bromoacetyl bromide and chloroacetyl chloride as alternative acylating agents, including “Reaction Conditions A” and “Reaction Conditions B”. The key intermediates 2-bromoacetamide 2b(R) and 2-chloracetamide 2a( / ?) were successfully synthesised, with a particular focus on optimising the conditions for the preparation of the target Compound 1. The optimal reaction conditions for each A-(2-haloacetyl)pyrrolidine product are summarised in Table 6.

[0759] “Reaction Conditions A” (2 M K2CO3 / CH2CI2) provided the most efficient and reproducible results. This approach led to high conversions, minimal side -product formation, and improved product stability, especially when chloroacetyl chloride (4a, X2= Cl) was used as the acylating reagent.

[0760] “Reaction Conditions B” (2 M K2CO3 / 2-MeTHF) resulted in lower conversions and increased impurity levels.

[0761] The 2-bromoacetamide product 2b( / ?) exhibited notable degradation under acylation conditions, especially at extended reaction times at room temperature, highlighting their higher reactivity and lower stability compared to the chloroacetyl derivatives 2a( / ?).

[0762] When comparing “Reaction Conditions A” and “Reaction Conditions B” to “Reaction Conditions C” and “Reaction Conditions D”, it was found that “Reaction Conditions A” and “Reaction Conditions B” provided superior yield, purity, and reaction efficiency. Neither “Reaction Conditions C” nor “Reaction Conditions D” offered significant improvements over “Reaction Conditions A”, emphasising its robustness for the A-acylation reaction of pyrrolidine 3a(R).

[0763] Base screening experiments identified aqueous K2CO3 as the most effective base for the acylation of pyrrolidine-2-carboxylate 3a( / ?) with chloroacetyl chloride (4a, X2= Cl) in CH2CI2 (“Reaction Conditions A”), yielding cleaner reactions with higher purity. Alternative bases such as K3PO4 and KHCO3 provided similar results.Summary

[0764] Overall, A- acylation of the pyrrolidine-2-carboxylate 3a( / ?) (HC1 salt or freebase) with chloroacetyl chloride in CH2CI2 at 0 °C (under “Reaction Conditions A”; entry 5, Table 6) produced the best results in terms of conversion, isolated yield, purity, and product stability.

[0765] Table 6. Optimal reaction conditions for the A-acylation reaction of pyrrolidine 3a( / ?).

[0766]

[0767] aHPLC analysis (sc_base_mcpr, 210 nm) performed after 1 h at 0 °C. Peak area was measured by manual integration.bIncomplete conversion: 1.21 area% of unreacted 3( / ?)a.

[0768] Preparation of Compound 1 (R) ( Step 5 )

[0769] The cyclisation reaction of A-(2-haloacetyl)pyrrolidine-2-carboxylate 2b( / ?) / 2a( / ?) was systematically investigated to optimise the synthesis of Compound 1( / ?). In this context, the cyclisation reaction with methanolic ammonia was examined under “Reaction Conditions A”, “Reaction Conditions B”, “Reaction Conditions C”, and “Reaction Conditions D”. The results demonstrated that substrate selection, ammonia concentration, solvent, and temperature significantly influenced reaction efficiency, yield, and impurity profile. The optimal cyclisation reaction conditions are summarised in Table 7.

[0770] Carboxylate 2a( / ?): The “Reaction Conditions B” using 7 N ammonia in MeOH (10 equiv) at 30 °C yielded the highest conversion and purity (98.6 area% Compound 1(R) by HPLC in 1 h). Comparable results (98.9 area%) were obtained under “Reaction Conditions A” with 7 N ammonia in MeOH (20 equiv) at room temperature.

[0771] Carboxylate 2b( / ?): The “Reaction Conditions C” using 2 N ammonia in MeOH (10 equiv) at RT was most effective, yielding 96.5 area% Compound 1(R) by HPLC while minimising side-product formation due to the low substrate concentration.

[0772] Key parameters affecting cyclisation reaction:Ammonia concentration and solvent. Higher ammonia concentrations (7 N) in methanol improved reaction rates and yields over 4 N or 2 N solutions. Alternative solvents (e.g. ethanol and isopropanol) led to side-reactions such as transesterification and slow conversion.

[0773] Temperature. Reactions at 30 °C reached completion faster than at room temperature, but extended reaction times (>20 h) did not provide additional yield benefits.

[0774] Substrate concentration. Dilution with excess ammonia solution increased the yield of Compound 1(R) and reduced the levels of oligomeric side-products. Maintaining a low substrate concentration favours the intramolecular lactam formation over competing intermolecular oligomerization.

[0775] Halogen leaving group. A-(2-bromoacetyl) derivative 2b( / ?) exhibited greater reactivity than A-(2-chloroacetyl) counterpart 2a( / ?), leading to faster cyclisation, but also increased oligomerization. With these substrates, high dilution is recommended to control side reactions.

[0776] Summary

[0777] Overall, the most effective protocols for Compound 1( / ?) synthesis were the “Reaction Conditions A” and “Reaction Conditions B” for 2a( / ?) (7 N ammonia in MeOH; entries 1-2, Table 7) and the “Reaction Conditions C” for 2b( / ?) (2 N ammonia in MeOH; entry 3, Table 7), achieving high yields, optimal purity, and minimal side reactions.

[0778] Table 7. Optimal reaction conditions for the cyclisation reaction of 2b( / ?) / 2a( / ?).

[0779]

[0780] aHPLC analysis (XBridge-C18_05-80_Phos, 195 nm) performed after ca. 20 h of reaction. Peak area was measured by manual integration.Example 6: General Experimental

[0781] Unless otherwise stated, all starting materials and reagents were purchased through commercial sources or synthesised according to methods known in the art.

[0782] N-Acylation Reaction of Pyrrolidine 3a(R

[0783] “Reaction Conditions A” - General Experimental Procedure

[0784] The reaction was performed in an 8 mL glass vial equipped with a stirring bar. Potassium carbonate, 2 M in water (3.4 equiv), was added to a stirred solution of the pyrrolidine-2-carboxylate 3a( / ?) in CH2CI2 (11 vol) and the mixture was cooled to 0 °C (ice bath). The dihalide 4a / 4d (1.5 equiv) was then added drop wise. The biphasic reaction mixture was vigorously stirred (1400 rpm) at 0 °C for 1 hour and then at room temperature overnight. LCMS / HPLC (sc_base, 210 nm) monitoring after 1 hour at 0 °C (si), an additional hour at RT (s2), and ca. 18 h at RT (s3). The reaction mixture was partitioned between water (10 vol) and CH2CI2 (10 vol), and the aqueous layer (pH 8-9) was further extracted with CH2CI2 (10 vol). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the crude acylated product.

[0785] “Reaction Conditions B” - General Experimental Procedure

[0786] The reaction was performed in an 8 mL glass vial equipped with a stirring bar. Potassium carbonate, 2 M in water (1.8 equiv), was added to a stirred solution of the pyrrolidine-2-carboxylate 3a( / ?) in 2-MeTHF (6 vol) and the mixture was cooled to 0 °C (ice bath). The dihalide 4a / 4d (1.5 equiv) was then added drop wise. The biphasic reaction mixture was vigorously stirred (1400 rpm) at 0 °C for 1 hour and then at room temperature overnight. LCMS / HPLC (sc_base, 210 nm) monitoring after 1 hour at 0 °C (si), an additional hour at RT (s2), and ca. 18 h at RT (s3). The reaction mixture was diluted with 2-MeTHF (10 vol), and the aqueous layer (pH 8-9) was separated and discarded. The organic layer was washed with aqueous NaCl (25% w / v; 10 vol), dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the crude acylated product.

[0787] “Reaction Conditions C” - General Experimental Procedure

[0788] The reaction was performed in an 8 mL glass vial equipped with a stirring bar under nitrogen. A solution of pyrrolidine-2-carboxylate hydrochloride 3a( / ?). HCl in CDCI3 (12.3 vol) was cooled to -10 °C (ice / salt bath) and treated sequentially with triethylamine (2.4 equiv) and dihalide 4a / 4d (2.4 equiv) in CDCI3 (12.3 vol). After stirring for 2 h at -10 °C (HPLC / LCMSmonitoring), the reaction was quenched with water (12.3 vol) and the layers were separated (aqueous layer was discarded; pH 2). The organic layer was washed with sat. aq. NaHCCh (12.3 vol; pH 8), brine (12.3 vol; pH 7), dried over NaiSCU, filtered, and concentrated under reduced pressure to afford the crude acylated product.

[0789] “Reaction Conditions D” - General Experimental Procedure

[0790] The reaction was performed in an 8 mL glass vial equipped with a stirring bar under nitrogen. Potassium carbonate, 1 M in water (1.3 equiv) was added to a solution of pyrrolidine -2-carboxylate 3a( / ?) in CH2CI2 (25 vol) and the mixture was cooled to 0 °C (ice bath). The dihalide 4a / 4d (1.3 equiv) was added in one portion to the vigorously stirred biphasic solution. The reaction mixture was stirred at 0 °C for 2 h (HPLC / LCMS monitoring). The organic layer was separated, and the aqueous layer (pH 8-9) was further extracted with CH2CI2 (2 x 14 vol). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the crude acylated product.

[0791] Preparation of Compound 2a(R)

[0792] The reaction was performed in 100 mL glass round-bottom flask with magnetic stirring. Potassium carbonate, 2 M in water (12.5 mL, 4.6 equiv), was added to a stirred solution of the pyrrolidine-2-carboxylate hydrochloride 3a( / ?) HCl (1.155 g, 5.45 mmol) in CH2CI2 (12.5 mL, 11 vol) at 0 °C (ice bath; gas release was expected but not observed). After 2 min (resulting in a clear biphasic system with pH 8), 2-chloroacetyl chloride (1.5 equiv) was added dropwise and the mixture was vigorously stirred at 0 °C for 1 hour and then at room temperature overnight. The reaction mixture was partitioned between water (10 vol) and CH2CI2 (10 vol), and the aqueous layer (pH 8) was further extracted with CH2CI2 (10 vol). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the crude acylated product 2a( / ?) (batch 22020153 -77-A, 1.329 g, 99% uncorrected yield) as a slightly yellow oil (98.29 area% by HPLC, 210 nm). This material was combined with the crude 2a( / ?) obtained from previous experiment into a single batch (79-A, 2.11 g) and then purified by flash chromatography (silica gel, 20-100% EtOAc in heptane) to provide the N-(2-chloroacetyl)pyrrolidine 2a( / ?) (1.86 g, batch 22020153-79-A-l) as a colorless oil (97.67% purity by HPLC), containing the minor impurity 21 (2.33 area%).

[0793] Preparation of Compound 2b(R)

[0794] Potassium carbonate, 2 M in water (11 mL, 4.6 equiv), was added to a stirred solution of the pyrrolidine-2-carboxylate hydrochloride 3a( / ?)*HCl (1.0 g, 5.7 mmol; batch 22020153-76-B) in dry CH2CI2 (11 mL, 11 vol) at 0 °C (ice bath). After 10 min, 2-bromoacetyl chloride (1.5 equiv) was added dropwise and the mixture was stirred at 0 °C for 1 hour and then at room temperature overnight (full conversion by LCMS). The reaction mixture was partitioned between water (10 vol) and CH2CI2 (10 vol), and the aqueous layer was further extracted with CH2CI2 (2x10 vol). The combined organic layers were dried over Na2SC>4, filtered, and concentrated under reduced pressure. The residue (orange oil, ca. 1.3 g) was purified by flash chromatography (silica gel, 0-50% EtOAc in heptane) to provide the A-(2-bromoacetyl)pyrrolidine 2b( / ?) (1.14 g, 83% yield) as a colorless oil (99.55% purity by HPLC at 195 nm).

[0795] Cyclisation Reaction of Pyrrolidine 2b(R) / 2a(R)

[0796] “Reaction Conditions A” - General Experimental Procedure

[0797] The reaction was performed in an 8 mL glass vials equipped with stirring bar and sealed with a Thermoset screw cap. Compound 2b( / ?) / 2a( / ?) was dissolved in 7 N ammonia solution in MeOH (20 equiv; 12.4 vol) and the mixture was stirred at room temperature. Reaction progress was monitored by HPLC / LCMS (XBridge-C18_05-80_Phos, 195 nm) at four intervals: 1 h (si), 5 h (s2), ca. 20 h (s3), and 4 days (s4). After 4 days at RT, the reaction mixture was discarded without further treatment.

[0798] “Reaction Conditions B” - General Experimental Procedure

[0799] The reaction was performed in an 8 mL glass vials equipped with stirring bar and sealed with a Thermoset screw cap. Compound 2b( / ?) / 2a( / ?) was dissolved in 7 N ammonia solution in MeOH (10 equiv; 5.8 vol) and the mixture was stirred at 30 °C. Reaction progress was monitored by HPLC / LCMS (XBridge-C18_05-80_Phos, 195 nm) at four time points: 1 hour (si), 5 hours (s2), ca. 20 hours (s3), and 4 days (s4). After 4 days at 30 °C, the reaction mixture was discarded without further treatment.

[0800] “Reaction Conditions C” - General Experimental Procedure

[0801] The reaction was performed in an 8 mL glass vials equipped with stirring bar and sealed with a Thermoset screw cap. Compound 2b( / ?) / 2a( / ?) was dissolved in 2 N ammonia solution in MeOH (10 equiv; 17.2 vol) and the mixture was stirred at room temperature. Reaction progress was monitored by HPLC / LCMS (XBridge-C18_05-80_Phos, 195 nm) at four time points: 1 hour (si), 5 hours (s2), ca. 20 hours (s3), and 4 days (s4). After 4 days at RT, the reaction mixture was discarded without further treatment.

[0802] “Reaction Conditions D” - General Experimental ProcedureThe reaction was performed in an 8 mL glass vials equipped with stirring bar and sealed with a Thermoset screw cap. Compound 2b( / ?) / 2a( / ?) was dissolved in 4 N ammonia solution in MeOH (5 equiv; 4.5 vol) and the mixture was stirred at room temperature. Reaction progress was monitored by HPLC / LCMS (XBridge-C18_05-80_Phos, 195 nm) at four time points: 1 hour (si), 5 hours (s2), ca. 20 hours (s3), and 4 days (s4). After 4 days at RT, the reaction mixture was discarded without further treatment.

[0803] Analytical Methods

[0804] HPLC Method: Sc_Base_MCPR (210 nm)

[0805] Instrument: Agilent 1260. Bin. Pump: G1312B, Degasser. Autosampler 1260. Column Comp. 1260. Detection: G1315C DAD (210, 220 and 210-320 nm), PDA (210-320 nm). Column: Waters XSelect CSH C18 (50x2.1 mm, 3.5 pm). Flow: 0.8 mL / min. Column temp: 25°C. Eluent A: 10 mM NH4HCO3 in MilliQ water (pH 9.5). Eluent B: acetonitrile. Gradient: t=0 min 5% B, t=4.5 min 98% B, t=6 min 98% B. Postrun: 2 min, 5% B.

[0806] LCMS Method: Sc_Base (210 nm)

[0807] Instrument: Agilent 1260 Infinity II. Bin. Pump: 1260 G7112B. Multisampler: 1260 G7167A. 1260 MCT G7116A Column Comp.: 1260 MCT G7116A. Detection: DAD G7115A (210, 220 and 210-320 nm), PDA (210-320 nm), MSD G6130B (ESI pos / neg) mass range 90- 1500. Column: XSelect CSH C18 (30x2.1 mm, 3.5 pm). Flow: 1 mL / min, Column temp: 25°C. Eluent A: 10 mM NH4HCO3 in water (pH 9.5). Eluent B: acetonitrile. Gradient: t=0 min 5% B, t=1.6 min 98% B, t=3 min 98% B. Postrun: 1.2 min.

[0808] HPLC Method: XBridge-C18_05-80_Phos (195 nm)

[0809] Instrument: Agilent 1100. Quat. Pump: G1311A. Autosampler 1100. Column Comp.

[0810] 1100. Detection: G1315A DAD (195 nm and 210-320 nm). Column: XBridge C18 (150x4.6mm, 3.5 pm). Flow: 1.0 mL / min. Column temp: 30°C. Eluent A: 0.1% Phosphoric acid in MilliQ water. Eluent B: acetonitrile. Gradient: t=0 min 5% B, t=0.1 min 5% B, t= 10 min 35% B, t=15 min 80% B, t=19 min 80% B, t=20 min 5% B, t=25 min 5% B.

[0811] LCMS Method: XBridge-C18_05-80_FA (195 nm)

[0812] Instrument: Agilent 1260 Infinity with SQ-MSD. Quat. Pump: G1311A. Autosampler 1100. Column Comp. 1100. Detection: DAD G1315A (195 nm and 210-320 nm), PDA (210-320 nm), MSD G6130B (ESI pos / neg) mass range 100-1000. Column: XBridge C18(150x4.6mm, 3.5 pm). Flow: 1.0 mL / min. Column temp: 30°C. Eluent A: 0.1% Formic acid in water. Eluent B: 0.1% Formic acid in MeCN. Gradient: t=0 min 5% B, t=0.1 min 5% B, t=10 min 35% B, t=15 min 80% B, t=19 min 80% B, t=20 min 5% B, t=25 min 5% B.

[0813] Example 7: Determination of Impurities

[0814] The presence of impurities was determined by HPLC analyses, as described below. Equipment and Conditions A

[0815] HPLC: Liquid chromatograph equipped with an automatic injector, UV or a PDA detector, column oven and chromatographic software. Column: Waters Atlantis T3, 150 x 4.6 mm, 3.0 pm (PN# 186003729). Analytical balance with 0.01 mg resolution. Sonicator bath.

[0816] Chromatographic Conditions A

[0817]

[0818] Equipment and Conditions B

[0819] HPLC: Liquid chromatograph equipped with an automatic injector, QDa detector, column oven and chromatographic software. Column: Waters Atlantis T3, 150 x 4.6 mm, 3.0 pm (PN# 186003729). Analytical balance with 0.01 mg resolution. Sonicator bath.

[0820] Chromatographic Conditions B

[0821]

[0822] Equipment and Conditions C

[0823] HPLC: Liquid chromatograph equipped with an automatic injector, UV or a PDA detector, column oven and chromatographic software. Column: ChiralPak ID-3, 150 x 4.6 mm, 3.0 pm (ref 84524). Analytical balance with 0.01 mg resolution. Sonicator bath.

[0824] Chromatographic Conditions C

[0825]

[0826]

[0827] Equipment and Conditions D

[0828] HPLC: Liquid chromatograph equipped with an automatic injector, UV or a PDA detector, column oven and chromatographic software. Column: X-Bridge Cl 8, 150 x 4.6 mm, 3.5 pm (PN# 186003034). Analytical balance with 0.01 mg resolution. Sonicator bath.

[0829] Chromatographic Conditions D

[0830]

[0831]

[0832] General Conditions

[0833] Column conditioning: The system was purged in all lines. In order to initially condition the column with mobile phase, the initial mobile phase composition was flowed through the system for at least 30 min for Chromatographic Conditions A and B, for at least 120 min for Chromatographic Conditions C, for at least 25 min for Chromatographic Conditions D, at a flow rate of 1.0 mL / min. The oven temperature was set. The detector lamp was warmed for at least 30 min prior to commencement of the injector sequence.117

[0834] mpurity g

[0835] PLC results for several batches of isolated API (NNZ-2591) purified solid.

[0836]

[0837] 118

[0838] tability Data for batch RC-35674-02 stored at 25 °C ± 2 °C / 60 % RH ± 5 % RH (Chromatographic Conditions A).

[0839]

[0840] tability Data for batch GV-37468-03 stored at 25 °C ± 2 °C / 60 % RH ± 5 % RH (Chromatographic Conditions A).

[0841]

[0842] 119

[0843] tability Data for batch GV-37468-03 stored at 40 °C ± 2 °C / 75 % RH ± 5 % RH (Chromatographic Conditions A).

[0844]

[0845] 120

[0846] mpurity h

[0847] PLC impurity profile and total impurities for several batches of NNZ-2591 (Chromatographic Conditions A).

[0848]

[0849] 121

[0850] tability Data for batch GV-37468-03 stored at 25 °C ± 2 °C / 60 % RH ± 5 % RH (Chromatographic Conditions A).

[0851]

[0852] tability Data for batch GV-37468-03 stored at 40 °C ± 2 °C / 75 % RH ± 5 % RH (Chromatographic Conditions A).

[0853]

[0854] 122

[0855] tability Data for batch 100001 stored at 40 °C ± 2 °C / 75 % RH ± 5 % RH (Chromatographic Conditions A).

[0856]

[0857] 123

[0858] mpurity 2a

[0859] PLC results for several batches of isolated API (NNZ-2591) purified solid (Chromatographic Conditions B).

[0860]

[0861] 124

[0862] mpurity i and Impurity k

[0863] PLC impurity profile and total impurities for several batches of NNZ-2591 (Chromatographic Conditions A).

[0864]

[0865] 125

[0866] mpurity 1(5')

[0867] PLC results for several batches of isolated API (NNZ-2591) purified solid (Chromatographic Conditions C).

[0868]

[0869] 126

[0870] mpurity c

[0871] PLC impurity profile and total impurities for batches of NNZ-2591 (Chromatographic Conditions A).

[0872]

[0873] 127

[0874] PLC in-process results obtained for batches RC35672, GV-37464, and CZ-46672 (Chromatographic Conditions D).

[0875]

[0876]

[0877] T 12.73 / RRT 2.29 correlates to Impurity c.

[0878] 10159 is Impurity 2a( / ?).Itemised List of Embodiments

[0879] 1. A process for preparing a bicyclic glycine -proline compound of Formula 1 comprising a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1:

[0880]

[0881] Formula 2 Formula 1;

[0882] wherein

[0883] R1is a terminal group; and

[0884] X1is a halogen.

[0885] 2. The process of item 1, wherein the cyclisation reaction is performed in the presence of an ammonia reagent.

[0886] 3. The process of item 1 or item 2, wherein R1is selected from the group consisting of -OH and -OC1-6alkyl.

[0887] 4. The process of any one of items 1 to 3, wherein R1is -OCH3.

[0888] 5. The process of any one of items 1 to 4, wherein X1is chlorine.

[0889] 6. The process of any one of items 2 to 5, wherein the ammonia reagent is selected from the group consisting of ammonia in organic solvent, gaseous ammonia, liquid ammonia, sodium amide, and combinations thereof.

[0890] 7. The process of any one of items 2 to 6, wherein the ammonia reagent is ammonia in organic solvent.

[0891] 8. The process of item 7, wherein the organic solvent is an alcoholic solvent, and the ammonia reagent is selected from the group consisting of ammonia in methanol solvent, ammonia in ethanol solvent, ammonia in isopropanol solvent, and combinations thereof.

[0892] 9. The process of any one of items 2 to 8, wherein the ammonia reagent is ammonia in methanol solvent.

[0893] 10. The process of any one of items 2 to 9, wherein the ammonia reagent is provided in a concentration of between about 1.0 N and 10 N, between about 4.0 N and 9.0 N, or betweenabout 6.0 N and 8.0 N.

[0894] 11. The process of any one of items 2 to 10, wherein the ammonia reagent is provided in a molar equivalent amount of ammonia of between about 0.1 and 40, between about 1.0 and 30, between about 5.0 and 25, or between about 5.0 to 20, relative to the molar amount of the compound of Formula 2.

[0895] 12. The process of any one of items 1 to 11, wherein the cyclisation reaction is performed in the presence of a chlorinated hydrocarbon solvent, an ether solvent, an organic nitrile solvent, or a combination thereof.

[0896] 13. The process of any one of items 1 to 12, wherein the cyclisation reaction is performed at between about 10 °C and 50 °C, between about 20 °C and 40 °C, or between about 25 °C and 35 °C.

[0897] 14. The process of any one of items 1 to 12, wherein the cyclisation reaction provides at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2 to the compound of Formula 1.

[0898] 15. The process of item 1, wherein the compound of Formula 2 is a compound of Formula 2a:

[0899]

[0900] Formula 2a.

[0901] 16. The process of any one of items 1 to 15, further comprising preparing a compound of Formula 2 via an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0902]

[0903] Formula 3 Formula 4 Formula 2;

[0904] whereinR1is a terminal group;

[0905] X1is a halogen; and

[0906] X2is a halogen.

[0907] 17. The process of item 16, wherein R1is -OCH3.

[0908] 18. The process of item 16 or item 17, wherein X1is chlorine and X2is chlorine.

[0909] 19. The process of any one of items 16 to 18, wherein the dihalide compound of Formula 4 is provided in a molar equivalent amount of between about 0.1 and 20, between about 1.0 and 10, between about 1.1 and 5, or between about 1.2 and 1.7 relative to the molar amount of the compound of Formula 3.

[0910] 20. The process of any one of items 16 to 19, wherein the N-acylation reaction is performed in the presence of a base reagent.

[0911] 21. The process of item 20, wherein the base reagent is potassium carbonate (K2CO3). 22. The process of item 21, wherein the potassium carbonate (K2CO3) is provided as an aqueous solution.

[0912] 23. The process of item 22, wherein the aqueous potassium carbonate solution has a concentration of between about 0.5 M and 10 M, between about 1.0 M and 5.0 M, or between about 1.5 M and 2.5 M.

[0913] 24. The process of any one of items 21 to 23, wherein the potassium carbonate (K2CO3) is provided in a molar equivalent amount of between about 0.5 and 5.0, between about 0.75 and 4.0, or between about 1.0 and 3.0, relative to the molar amount of the compound of Formula 3.

[0914] 25. The process of any one of items 16 to 24, wherein the N-acylation reaction is performed in the presence of a chlorinated hydrocarbon solvent, an ether solvent, or a combination thereof.

[0915] 26. The process of item 25, wherein the organic solvent is dichloromethane (DCM).

[0916] 27. The process of item 25, wherein the organic solvent is 2 -methyltetrahydrofuran (2-MeTHF).

[0917] 28. The process of any one of items 16 to 27, wherein a reaction mixture comprising a compound of Formula 3 is initially cooled to between about -30 °C to 10 °C, between about -20 °C to 10 °C, or between about -10 °C to 10 °C, immediately prior to the reaction with a dihalide compound of Formula 4.29. The process of any one of items 16 to 28, wherein a reaction mixture comprising a compound of Formula 3 and a dihalide compound of Formula 4 is allowed to warm to between about 10 °C and 50 °C, between about 15 °C and 40 °C, between about 15 °C and 30 °C, or between about 15 °C and 25 °C, where the temperature is maintained until completion of the reaction.

[0918] 30. The process of any one of items 16 to 29, wherein the N-acylation reaction provides at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2.

[0919] 31. The process of item 16, wherein the compound of Formula 3 is a compound of Formula 3a:

[0920]

[0921] Formula 3a.

[0922] 32. The process of any one of items 1 to 31, wherein the bicyclic glycine-proline compound of Formula 1 is a bicyclic glycine-proline compound of Formula 1(R):

[0923]

[0924] Formula 1(R).

[0925] 33. A bicyclic gly cine-proline compound of Formula 1:

[0926]

[0927] Formula 1;

[0928] prepared by the process of any one of items 1 to 31.

[0929] 34. A process for preparing a compound of Formula 2 comprising an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0930]

[0931] Formula 3 Formula 4 Formula 2;

[0932] wherein

[0933] R1is a terminal group;

[0934] X1is a halogen; and

[0935] X2is a halogen.

[0936] 35. The process of item 34, wherein R1is -OCH3.

[0937] 36. The process of item 34 or item 35, wherein X1is chlorine and X2is chlorine.

[0938] 37. The process of item 34, wherein the compound of Formula 3 is a compound of Formula 3a:

[0939]

[0940] Formula 3a.

[0941] 38. The process of any one of items 34 to 37, further comprising reacting a compound of Formula 2 in the presence of an ammonia reagent to form the bicyclic glycine-proline compound of Formula 1:

[0942]

[0943] Formula 2 Formula 1;

[0944] wherein

[0945] R1is a terminal group; and

[0946] X1is a halogen.

[0947] 39. The process of item 38, wherein R1is -OCH3.40. The process of item 38 or item 39, wherein X1is chlorine.

[0948] 41. A composition comprising a bicyclic glycine -proline compound of Formula 1:

[0949]

[0950] Formula 1;

[0951] and one or more excipients, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, or 0.0001.

[0952] 42. A composition comprising a bicyclic glycine -proline compound of Formula 1:

[0953]

[0954] Formula 1;

[0955] and one or more excipients, wherein the composition is substantially free of impurities.

[0956] 43. A composition comprising a compound of Formula 1:

[0957]

[0958] Formula 1;

[0959] wherein Impurity b:

[0960]

[0961] Impurity b;

[0962] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.44. A composition comprising a compound of Formula 1:

[0963]

[0964] Formula 1;

[0965] wherein Impurity g:

[0966]

[0967] Impurity g;

[0968] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0969] 45. A composition comprising a compound of Formula 1:

[0970]

[0971] Formula 1;

[0972] wherein Impurity h:

[0973]

[0974] Impurity h;

[0975] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0976] 46. A composition comprising a compound of Formula 1:

[0977]

[0978] Formula 1;

[0979] wherein a compound of Formula 2:

[0980]

[0981] Formula 2;

[0982] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001, wherein R1is a terminal group; and X1is a halogen.

[0983] 47. The composition of claim 46, wherein X1is selected from the group consisting of chlorine and bromine.

[0984] 48. A composition comprising a compound of Formula 1:

[0985]

[0986] Formula 1;

[0987] wherein Impurity 2a:

[0988]

[0989] Impurity 2a;

[0990] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001,0.00001, or 0.000001.49. A composition comprising a compound of Formula 1:

[0991]

[0992] Formula 1;

[0993] wherein Impurity 1:

[0994]

[0995] Impurity l;

[0996] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0997] 50. A composition comprising a compound of Formula 1:

[0998]

[0999] Formula 1;

[1000] wherein Impurity j:

[1001]

[1002] Impurity j;

[1003] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[1004] 51. A composition comprising a compound of Formula 1:

[1005]

[1006] Formula 1;

[1007] wherein Impurity k:

[1008]

[1009] Impurity k;

[1010] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[1011] 52. A composition comprising a compound of Formula 1(R):

[1012]

[1013] wherein Impurity 1(S):

[1014]

[1015] Impurity 1(S):

[1016] if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[1017] 53. A composition comprising a compound of Formula 1:

[1018]

[1019] Formula 1;

[1020] wherein Impurity c:

[1021]

[1022] Impurity c;

[1023] if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

Claims

Claims1. A process for preparing a bicyclic glycine -proline compound of Formula 1 comprising a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1:Formula 2 Formula 1;whereinR1is a terminal group; andX1is a halogen.

2. The process of claim 1, wherein the cyclisation reaction is performed in the presence of an ammonia reagent.

3. The process of claim 1 or claim 2, wherein R1is selected from the group consisting of -OH and -OC1-6alkyl.

4. The process of any one of claims 1 to 3, wherein R1is -OCH3.

5. The process of any one of claims 1 to 4, wherein X1is chlorine.

6. The process of any one of claims 2 to 5, wherein the ammonia reagent is selected from the group consisting of ammonia in organic solvent, gaseous ammonia, liquid ammonia, sodium amide, and combinations thereof.

7. The process of any one of claims 2 to 6, wherein the ammonia reagent is ammonia in organic solvent.

8. The process of claim 7, wherein the organic solvent is an alcoholic solvent, and the ammonia reagent is selected from the group consisting of ammonia in methanol solvent, ammonia in ethanol solvent, ammonia in isopropanol solvent, and combinations thereof.

9. The process of any one of claims 2 to 8, wherein the ammonia reagent is ammonia in methanol solvent.

10. The process of any one of claims 2 to 9, wherein the ammonia reagent is provided in a concentration of between about 1.0 N and 10 N, between about 4.0 N and 9.0 N, or betweenabout 6.0 N and 8.0 N.

11. The process of any one of claims 2 to 10, wherein the ammonia reagent is provided in a molar equivalent amount of ammonia of between about 0.1 and 40, between about 1.0 and 30, between about 5.0 and 25, or between about 5.0 to 20, relative to the molar amount of the compound of Formula 2.

12. The process of any one of claims 1 to 11, wherein the cyclisation reaction is performed in the presence of a chlorinated hydrocarbon solvent, an ether solvent, an organic nitrile solvent, or a combination thereof.

13. The process of any one of claims 1 to 12, wherein the cyclisation reaction is performed at between about 10 °C and 50 °C, between about 20 °C and 40 °C, or between about 25 °C and 35 °C.

14. The process of any one of claims 1 to 13, wherein the cyclisation reaction provides at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2 to the compound of Formula 1.

15. The process of claim 1, wherein the compound of Formula 2 is a compound of Formula 2a:Formula 2a.

16. The process of any one of claims 1 to 15, further comprising preparing a compound of Formula 2 via an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:Formula 3 Formula 4 Formula 2;whereinR1is a terminal group;X1is a halogen; andX2is a halogen.

17. The process of claim 16, wherein R1is -OCH3.

18. The process of claim 16 or claim 17, wherein X1is chlorine and X2is chlorine.

19. The process of any one of claims 16 to 18, wherein the dihalide compound of Formula 4 is provided in a molar equivalent amount of between about 0.1 and 20, between about 1.0 and 10, between about 1.1 and 5, or between about 1.2 and 1.7 relative to the molar amount of the compound of Formula 3.

20. The process of any one of claims 16 to 19, wherein the N-acylation reaction is performed in the presence of a base reagent.

21. The process of claim 20, wherein the base reagent is potassium carbonate (K2CO3).

22. The process of claim 21, wherein the potassium carbonate (K2CO3) is provided as an aqueous solution.

23. The process of claim 22, wherein the aqueous potassium carbonate solution has a concentration of between about 0.5 M and 10 M, between about 1.0 M and 5.0 M, or between about 1.5 M and 2.5 M.

24. The process of any one of claims 21 to 23, wherein the potassium carbonate (K2CO3) is provided in a molar equivalent amount of between about 0.5 and 5.0, between about 0.75 and 4.0, or between about 1.0 and 3.0, relative to the molar amount of the compound of Formula 3.

25. The process of any one of claims 16 to 24, wherein the N-acylation reaction is performed in the presence of a chlorinated hydrocarbon solvent, an ether solvent, or a combination thereof.

26. The process of claim 25, wherein the organic solvent is dichloromethane (DCM).

27. The process of claim 25, wherein the organic solvent is 2 -methyltetrahydrofuran (2-MeTHF).

28. The process of any one of claims 16 to 27, wherein a reaction mixture comprising a compound of Formula 3 is initially cooled to between about -30 °C to 10 °C, between about -20 °C to 10 °C, or between about -10 °C to 10 °C, immediately prior to the reaction with a dihalide compound of Formula 4.

29. The process of any one of claims 16 to 28, wherein a reaction mixture comprising a compound of Formula 3 and a dihalide compound of Formula 4 is allowed to warm to between about 10 °C and 50 °C, between about 15 °C and 40 °C, between about 15 °C and 30 °C, or between about 15 °C and 25 °C, where the temperature is maintained until completion of the reaction.

30. The process of any one of claims 16 to 29, wherein the N-acylation reaction provides at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2.

31. The process of claim 16, wherein the compound of Formula 3 is a compound of Formula 3a:Formula 3a.

32. The process of any one of claims 1 to 31, wherein the bicyclic glycine -proline compound of Formula 1 is a bicyclic glycine -proline compound of Formula 1(R):Formula 1(R).

33. A bicyclic gly cine-proline compound of Formula 1:Formula 1;prepared by the process of any one of claims 1 to 31.

34. A process for preparing a compound of Formula 2 comprising an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:Formula 3 Formula 4 Formula 2;whereinR1is a terminal group;X1is a halogen; andX2is a halogen.

35. The process of claim 34, wherein R1is -OCH3.

36. The process of claim 34 or claim 35, wherein X1is chlorine and X2is chlorine.

37. The process of claim 34, wherein the compound of Formula 3 is a compound of Formula 3a:Formula 3a.

38. The process of any one of claims 34 to 37, further comprising reacting a compound of Formula 2 in the presence of an ammonia reagent to form the bicyclic glycine-proline compound of Formula 1:Formula 2 Formula 1;whereinR1is a terminal group; andX1is a halogen.

39. The process of claim 38, wherein R1is -OCH3.

40. The process of claim 38 or claim 39, wherein X1is chlorine.

41. A composition comprising a bicyclic glycine -proline compound of Formula 1:Formula 1;and one or more excipients, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001.

42. A composition comprising a bicyclic glycine -proline compound of Formula 1:Formula 1;and one or more excipients, wherein the composition is substantially free of impurities.

43. A composition comprising a compound of Formula 1:Formula 1;wherein Impurity b:Impurity b;if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

44. A composition comprising a compound of Formula 1:Formula 1;wherein Impurity g:Impurity g;if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

45. A composition comprising a compound of Formula 1:Formula 1;wherein Impurity h:Impurity h;if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

46. A composition comprising a compound of Formula 1:Formula 1;wherein a compound of Formula 2:Formula 2;if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001, wherein R1is a terminal group; and X1is a halogen.

47. The composition of claim 46, wherein X1is selected from the group consisting of chlorine and bromine.

48. A composition comprising a compound of Formula 1:Formula 1;wherein Impurity 2a:Impurity 2a;if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00001, or 0.000001.

49. A composition comprising a compound of Formula 1:Formula 1;wherein Impurity l:Impurity l;if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

50. A composition comprising a compound of Formula 1:Formula 1;wherein Impurity j:Impurity j;if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

51. A composition comprising a compound of Formula 1:Formula 1;wherein Impurity k:Impurity k;if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

52. A composition comprising a compound of Formula 1(R):wherein Impurity 1(S):Impurity 1(S):if present, is in an amount (weight % of the amount of the compound of Formula 1(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

53. A composition comprising a compound of Formula 1:Formula 1;wherein Impurity c:Impurity c;if present, is in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.